Connective tissue disorder
MONDO:0003900A disease involving the connective tissue.
Also known as: connective tissue disease, connective tissue disease or disorder, connective tissue diseases, connective tissue disorder, connective tissue disorders, disease of connective tissue, disease or disorder of connective tissue, disease, connective tissue
4637 clinical trials for this condition and its sub-types, 70 tagged with Connective tissue disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Connective tissue disorder
-
Connective tissue neoplasm 1 trial · 2,404 incl. sub-types
13 sub-types
- Bone neoplasm 26 trials · 2,116 incl. sub-types Sub-types →
- Fibroblastic neoplasm 0 trials · 210 incl. sub-types Sub-types →
- Tumor of adipose tissue 1 trial · 98 incl. sub-types Sub-types →
- Chondrosarcoma 39 trials · 44 incl. sub-types Sub-types →
- Tenosynovial giant cell tumor 12 trials · 16 incl. sub-types Sub-types →
- Chondroma 4 trials Sub-types →
- Cholangiolocellular carcinoma 1 trial
- Solitary fibrous tumor/hemangiopericytoma 1 trial
- Angiomyxoma 0 trials
- Cartilage cancer 0 trials
- Dartoic leiomyoma 0 trials
- Lipofibromatosis-like neural tumor 0 trials
- Scirrhous adenocarcinoma 0 trials
-
Rheumatic disorder 90 trials · 1,792 incl. sub-types
30 sub-types
- Rheumatoid arthritis 576 trials · 795 incl. sub-types Sub-types →
- Lupus erythematosus 39 trials · 548 incl. sub-types Sub-types →
- Scleroderma 47 trials · 305 incl. sub-types Sub-types →
- Autoinflammatory syndrome 21 trials · 207 incl. sub-types Sub-types →
- Juvenile idiopathic arthritis 107 trials · 115 incl. sub-types Sub-types →
- Dermatomyositis 81 trials · 100 incl. sub-types Sub-types →
- Polymyalgia rheumatica 30 trials
- Rheumatic fever 16 trials
- Mixed connective tissue disease 15 trials
- Reactive arthritis 6 trials
- Camptodactyly-arthropathy-coxa vara-pericarditis syndrome 4 trials
- Gorham-Stout disease 2 trials
- Sweet syndrome 2 trials
- Palindromic rheumatism 1 trial
- Rheumatic disease of mitral valve 1 trial
- IL10-related early-onset inflammatory bowel disease 0 trials Sub-types →
- LAMA5-related multisystemic syndrome 0 trials
- Reye syndrome 0 trials
- Wissler syndrome 0 trials
- Acroosteolysis dominant type 0 trials
- Chondrocalcinosis 2 0 trials
- Fibroblastic rheumatism 0 trials
- Idiopathic juvenile osteoporosis 0 trials
- Intermittent hydrarthrosis 0 trials
- Interstitial granulomatous dermatitis with arthritis 0 trials
- Isolated sternocostoclavicular hyperostosis 0 trials
- Myalgia-eosinophilia syndrome associated with tryptophan 0 trials
- Progeria-associated arthropathy 0 trials
- Rheumatic pulmonary valve disease 0 trials
- Unexplained long-lasting fever/inflammatory syndrome 0 trials
-
Hereditary disorder of connective tissue 0 trials · 1,311 incl. sub-types
88 sub-types
- Systemic lupus erythematosus 516 trials · 522 incl. sub-types Sub-types →
- Chronic myelogenous leukemia, BCR-ABL1 positive 211 trials · 253 incl. sub-types Sub-types →
- Uterine corpus leiomyoma 104 trials · 109 incl. sub-types Sub-types →
- Acquired polycythemia vera 90 trials
- Chondrosarcoma 39 trials · 44 incl. sub-types Sub-types →
- Type 2 collagenopathy 0 trials · 39 incl. sub-types Sub-types →
- CHILD syndrome 37 trials
- Desmoid tumor 36 trials Sub-types →
- Familial isolated pituitary adenoma 1 trial · 31 incl. sub-types Sub-types →
- Inherited acute myeloid leukemia 1 trial · 25 incl. sub-types Sub-types →
- Hereditary periodic fever syndrome 5 trials · 24 incl. sub-types Sub-types →
- Marfan and Marfan-related disorder 1 trial · 22 incl. sub-types Sub-types →
- VEXAS syndrome 18 trials
- Hypermobility spectrum disorder 16 trials
- Peyronie disease 12 trials
- Aicardi-Goutieres syndrome 9 trials Sub-types →
- Autosomal recessive inherited pseudoxanthoma elasticum 7 trials
- Ewing sarcoma of bone 5 trials
- TREX1-related type 1 interferonopathy 0 trials · 5 incl. sub-types Sub-types →
- Camptodactyly-arthropathy-coxa vara-pericarditis syndrome 4 trials
- Chronic recurrent multifocal osteomyelitis 3 trials · 4 incl. sub-types Sub-types →
- Blau syndrome 3 trials
- Ollier disease 3 trials
- Autoimmune interstitial lung disease-arthritis syndrome 3 trials Sub-types →
- Deficiency of adenosine deaminase 2 3 trials
- Hereditary multiple osteochondromas 3 trials Sub-types →
- Inherited torticollis 3 trials
- Maffucci syndrome 2 trials
- STING-associated vasculopathy with onset in infancy 2 trials
- Familial chilblain lupus 2 trials Sub-types →
- Proteosome-associated autoinflammatory syndrome 2 trials Sub-types →
- Sweet syndrome 2 trials
- ADAR-related type 1 interferonopathy 0 trials · 1 incl. sub-types Sub-types →
- Singleton-Merten dysplasia 1 trial Sub-types →
- Arterial tortuosity syndrome 1 trial
- Cherubism 1 trial Sub-types →
- Hyperparathyroidism 2 with jaw tumors 1 trial
- Infantile myofibromatosis 1 trial Sub-types →
- Neonatal severe primary hyperparathyroidism 1 trial
- Ossification of the posterior longitudinal ligament of the spine 1 trial
- EMILIN-1-related connective tissue disease 0 trials
- Ehlers-Danlos syndrome, kyphoscoliotic type 1 0 trials
- IFIH1-related type 1 interferonopathy 0 trials Sub-types →
- IL10-related early-onset inflammatory bowel disease 0 trials Sub-types →
- LAMA5-related multisystemic syndrome 0 trials
- MASS syndrome 0 trials
- Pelger-Huet-like anomaly and episodic fever with abdominal pain 0 trials
- RNASEH2A-related type 1 interferonopathy 0 trials Sub-types →
- RNASEH2B-related type 1 interferonopathy 0 trials Sub-types →
- RNASEH2C-related type 1 interferonopathy 0 trials Sub-types →
- RNU7-1-related type 1 interferonopathy 0 trials Sub-types →
- SAMHD1-related type 1 interferonopathy 0 trials Sub-types →
- Sharpin-related autoinflammatory syndrome 0 trials
- Spondyloenchondrodysplasia with immune dysregulation 0 trials
- X-linked reticulate pigmentary disorder 0 trials
- Acroosteolysis dominant type 0 trials
- Aneurysmal bone cyst 0 trials
- Arterial tortuosity-bone fragility syndrome 0 trials
- Autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation 0 trials
- Autoinflammatory disease, X-linked 0 trials
- Autoinflammatory disease, multisystem, with immune dysregulation, X-linked 0 trials Sub-types →
- Autoinflammatory disease, systemic, with vasculitis 0 trials
- Autoinflammatory syndrome with immunodeficiency 0 trials
- Autoinflammatory syndrome with pyogenic bacterial infection and amylopectinosis 0 trials
- Autoinflammatory syndrome, familial, Behcet-like 0 trials Sub-types →
- Bone fragility with contractures, arterial rupture, and deafness 0 trials
- Brittle cornea syndrome 0 trials Sub-types →
- Chondrocalcinosis 2 0 trials
- Congenital progressive bone marrow failure-B-cell immunodeficiency-skeletal dysplasia syndrome 0 trials
- Diaphyseal medullary stenosis-bone malignancy syndrome 0 trials
- Encephalocraniocutaneous lipomatosis 0 trials
- Familial ossifying fibroma 0 trials
- Hyperparathyroidism 1 0 trials
- Hyperparathyroidism 3 0 trials
- Hyperparathyroidism 4 0 trials
- Idiopathic juvenile osteoporosis 0 trials
- Jugulotympanic paraganglioma 0 trials Sub-types →
- Juvenile hyaline fibromatosis 0 trials
- Linkeropathy 0 trials Sub-types →
- Multiple epiphyseal dysplasia due to collagen 9 anomaly 0 trials Sub-types →
- Multiple symmetric lipomatosis 0 trials Sub-types →
- Neonatal inflammatory skin and bowel disease 0 trials Sub-types →
- Progeroid and marfanoid aspect-lipodystrophy syndrome 0 trials
- Pseudo-TORCH syndrome 2 0 trials
- Psoriasis 14, pustular 0 trials
- Pyogenic arthritis-pyoderma gangrenosum-acne syndrome 0 trials
- Thrombocytopenia 6 0 trials
- Trichohepatoenteric syndrome 0 trials Sub-types →
-
Disease of the tendon 126 trials · 192 incl. sub-types
3 sub-types
- Tendinitis 24 trials · 77 incl. sub-types Sub-types →
- Tendon sheath disorder 0 trials · 30 incl. sub-types Sub-types →
- Tendinosis 17 trials
-
Benign connective and soft tissue neoplasm 0 trials · 101 incl. sub-types
5 sub-types
- Bone benign neoplasm 1 trial · 70 incl. sub-types Sub-types →
- Benign soft tissue neoplasm 0 trials · 16 incl. sub-types Sub-types →
- Benign lipomatous neoplasm 0 trials · 15 incl. sub-types Sub-types →
- Benign osteogenic neoplasm 0 trials Sub-types →
- Lipofibromatosis 0 trials
-
Fasciitis 7 trials · 97 incl. sub-types
6 sub-types
- Plantar fasciitis 85 trials
- Necrotizing fasciitis 7 trials
- Eosinophilic fasciitis 1 trial
- Ischemic fasciitis 0 trials
- Nodular fasciitis 0 trials Sub-types →
- Proliferative fasciitis 0 trials
-
Collagenopathy 3 trials · 42 incl. sub-types
3 sub-types
- Type 2 collagenopathy 0 trials · 39 incl. sub-types Sub-types →
- Disseminated eosinophilic collagen disease 0 trials
- Multiple epiphyseal dysplasia due to collagen 9 anomaly 0 trials Sub-types →
-
Interstitial cystitis 39 trials
-
Periostitis 0 trials · 16 incl. sub-types
2 sub-types
- Alveolar periostitis 16 trials
- Orbital periostitis 0 trials
-
Synovitis 15 trials
1 sub-type
- Gonococcal synovitis 0 trials
-
Overlapping connective tissue disease 2 trials · 15 incl. sub-types
2 sub-types
- Mixed connective tissue disease 15 trials
- MASS syndrome 0 trials
-
Panniculitis 3 trials · 6 incl. sub-types
6 sub-types
- Lipodermatosclerosis 1 trial
- Nodular non-suppurative panniculitis 1 trial
- Panniculitis and localized lipodystrophy 1 trial
- Cytophagic histiocytic panniculitis 0 trials
- Erythema nodosum 0 trials
- Lupus erythematosus panniculitis 0 trials
-
Enthesopathy 2 trials · 4 incl. sub-types
5 sub-types
- Enthesitis 2 trials
- Fibular collateral ligament bursitis 0 trials
- Olecranon bursitis 0 trials
- Pes anserinus tendinitis or bursitis 0 trials
- Tibial collateral ligament bursitis 0 trials
-
Ochronosis disorder 1 trial
1 sub-type
- Exogenous ochronosis 0 trials
-
Ainhum 0 trials
-
Interstitial keratitis 0 trials
1 sub-type
- Diffuse interstitial keratitis 0 trials
Most studied deeper sub-types
Showing the 400 most recently updated of 1882 trials in this tab.
-
Engineered t cells target FLT3 in Hard-to-Treat leukemia
Cure Recruiting nowResearchers are testing a new cell therapy called anti-FLT3 CAR-T (HG-CT-1) in adults and children with acute myeloid leukemia (AML) that has come back or stopped responding to standard treatment. The study is a Phase 1 dose-escalation trial, meaning its first goal is to find out…
Phase 1 • Sponsor: Hemogenyx Pharmaceuticals LLC • Aim: Cure
Last updated Sep 19, 2026 00:00 UTC
-
Can adding venetoclax make donor stem cell transplants safer for High-Risk blood cancers?
Cure Recruiting nowResearchers test whether adding venetoclax to a standard conditioning regimen called FLAMSA-treosulfan is safe for people with high-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or secondary acute myeloid leukemia who are receiving a donor blood stem cell trans…
Phase 1/2 • Sponsor: Heinrich-Heine University, Duesseldorf • Aim: Cure
Last updated Sep 18, 2026 00:00 UTC
-
Can a Four-Drug prep make curative transplant safer for older AML patients?
Cure Recruiting nowOlder adults with acute myeloid leukemia (AML) often fare poorly with chemotherapy alone, and a stem cell transplant can offer better long-term survival but carries a high risk of transplant-related death. Researchers are comparing two drug combinations given before a haploidenti…
Sponsor: Peking University People's Hospital • Aim: Cure
Last updated Sep 16, 2026 00:00 UTC
-
Half-Matched stem cells tested as cure for myelofibrosis
Cure Recruiting nowMyelofibrosis is a bone marrow disease that can lead to leukemia. A stem cell transplant from a matched donor can cure it, but many patients cannot find a match. This trial tests a new transplant protocol using half-matched family donors, with a special drug regimen before transp…
Sponsor: Peking University People's Hospital • Aim: Cure
Last updated Sep 16, 2026 00:00 UTC
-
Can a One-Time cell therapy silence lupus?
Cure Recruiting nowThis trial tests whether a single infusion of IM19 CAR-T cells can calm severe lupus that has not responded to standard treatments. Six adults with refractory systemic lupus erythematosus will receive the engineered immune cells, which are designed to target and reset the faulty …
Sponsor: Peking University Third Hospital • Aim: Cure
Last updated Sep 02, 2026 00:00 UTC
-
Supercharged donor cells aim to stop leukemia return after transplant
Cure Recruiting nowThis study tests a new approach to prevent leukemia from coming back after a stem cell transplant. It uses donor T cells that have been engineered to recognize and attack a specific target (HA-2) on leukemia cells. The trial enrolls adults with acute myeloid leukemia (AML) or mye…
Phase 3 • Sponsor: TScan Therapeutics, Inc. • Aim: Cure
Last updated Jul 24, 2026 00:00 UTC
-
New combo aims to wipe out stubborn leukemia traces
Disease control Recruiting nowThis study tests whether two drugs, venetoclax and revumenib, can control minimal residual disease (MRD) in people with acute myeloid leukemia (AML). MRD means small numbers of cancer cells remain after initial treatment, raising the risk of relapse. The trial enrolls about 8 par…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New pill combo aims to tackle tough leukemia
Disease control Recruiting nowThis early-stage trial tests two oral drugs, ziftomenib and quizartinib, together in adults with relapsed or hard-to-treat acute myeloid leukemia (AML) that has certain genetic markers. The goal is to find a safe and effective all-pill treatment for common AML subtypes. About 44 …
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Two-Drug combo targets leukemia that outsmarted its first treatment
Disease control Recruiting nowResearchers are testing whether adding an experimental drug called RVU120 to venetoclax can help adults with acute myeloid leukemia (AML) that has come back or stopped responding to earlier venetoclax-based treatment. The trial enrolls about 98 adults who have already failed a hy…
Phase 2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug combo shows promise in AML fight
Disease control Recruiting nowThis study tests whether adding the drug venetoclax to standard chemotherapy can better treat acute myeloid leukemia (AML) that is newly diagnosed or has come back. About 116 adults with AML or high-risk MDS will receive the combination. The goal is to see if the combo improves r…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New combo aims for deeper remission in older leukemia patients
Disease control Recruiting nowThis phase II trial tests whether adding gilteritinib to the usual two-drug therapy (azacitidine and venetoclax) can help older or frail adults with a specific type of acute myeloid leukemia (FLT3-mutated) achieve deeper remission. About 147 participants will be randomly assigned…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New cell therapy trial aims to tame stubborn autoimmune diseases
Disease control Recruiting nowThis early-phase trial is testing an injection called GT719 in 10 adults with moderate to severe autoimmune diseases that haven't responded to other treatments. The main goal is to check safety and find the right dose. Researchers will also look for signs that the therapy might h…
Early phase 1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Could a common arthritis drug tame rare immune disease symptoms?
Disease control Recruiting nowThis early study tests baricitinib, a drug already approved for other immune conditions, in 20 people with Job syndrome who also have lupus-like disease or eczema. Participants take the pill daily for 6 months. The main goal is to see if it is safe and tolerable, while also check…
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New Immune-Targeting drug surovatamig enters first human tests for arthritis and lupus
Disease control Recruiting nowThis Phase 1 trial tests surovatamig, a bispecific T-cell engager, in 48 adults with rheumatoid arthritis or systemic lupus erythematosus. The study gives the drug as injections in increasing doses to check safety, side effects, and how the body processes it. It is too early to k…
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New pill could transform leukemia treatment, phase 3 trial begins
Disease control Recruiting nowThis study tests a new oral drug, QTX-2101, combined with standard ATRA therapy for adults newly diagnosed with a low-risk form of acute promyelocytic leukemia (APL). The goal is to see if the oral capsule works as well as the current intravenous treatment. About 150 participants…
Phase 3 • Sponsor: Quetzal Therapeutics • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Could a targeted drug boost chemo success in leukemia?
Disease control Recruiting nowThis phase II trial is testing whether adding the drug venetoclax to standard chemotherapy can improve remission rates in younger patients with intermediate-risk acute myeloid leukemia (AML). About 153 participants will receive either standard chemo or a combination with venetocl…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Boosting transplants with donor immune cells to fight blood cancer relapse
Disease control Recruiting nowThis study tests whether giving donor white blood cells (lymphocytes) soon after a stem cell transplant can lower the chance of cancer returning in people with high-risk blood cancers like leukemia or lymphoma. Participants receive chemotherapy, a stem cell transplant, and then a…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New cocktail of 5 drugs targets tough leukemia
Disease control Recruiting nowThis phase 2 trial is testing a combination of five drugs (fludarabine, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin) in 270 people with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome that have specific genetic changes. The goal…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for leukemia patients: olverembatinib trial launches
Disease control Recruiting nowThis phase 2 trial tests whether the drug olverembatinib can safely control chronic myeloid leukemia (CML) in people who are newly diagnosed. About 50 adults will take the drug by mouth. Researchers will track side effects and how well the drug works. The study is currently recru…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for rare blood cancers: first human trial of PRT12396 begins
Disease control Recruiting nowThis early-stage study tests a new drug, PRT12396, in about 100 people with polycythemia vera or myelofibrosis—rare blood cancers. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug controls the disease, but this …
Phase 1 • Sponsor: Prelude Therapeutics Incorporated • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New combo therapy aims to tackle rare nasal cancer
Disease control Recruiting nowThis phase 2 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can shrink advanced squamous cell cancers of the nasal cavity and sinuses better than chemotherapy alone. About 35 adults with newly diagnosed, untreated stage II to IVb disease …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New combo therapy aims to boost remission in IDH2-Mutated AML
Disease control Recruiting nowThis phase II trial tests whether adding enasidenib to standard ASTX727 and venetoclax improves remission rates in older adults (or younger unfit patients) with newly diagnosed IDH2-mutated acute myeloid leukemia (AML). About 93 participants will be randomly assigned to receive e…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Lupus drug may shield heart and arteries
Disease control Recruiting nowThis study tests whether anifrolumab, a drug that blocks certain immune signals, can improve blood vessel function and reduce inflammation in people with lupus. About 45 adults with lupus will receive either the drug or a placebo over 8 months. Researchers will measure changes in…
Phase 2 • Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Targeted pill takes on rare skull base cancers
Disease control Recruiting nowThis phase 2 trial tests enasidenib, a daily pill that targets the IDH2 gene mutation, in 40 adults with rare cancers of the nasal cavity or skull base that have spread or come back. Participants take the drug once daily in 28-day cycles, and researchers will track how long the c…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for rare blood cancers: pacritinib trial opens for teens and adults
Disease control Recruiting nowThis study tests an oral drug called pacritinib in people aged 12 and older with myelodysplastic syndromes (MDS) or related blood cancers (MDS/MPN). The goal is to find the best dose and see if it can shrink or control the disease. Participants take capsules twice daily for up to…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Could detoxing metals boost chemo for leukemia?
Disease control Recruiting nowThis early-stage trial is testing whether two drugs that lower metal levels in the body can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) respond better to chemotherapy. The study will enroll 58 adults and aims to find the safest dose and check f…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for Tough-to-Treat leukemia: multiple drug cocktails tested
Disease control Recruiting nowThis phase II trial tests several experimental drug combinations against the standard treatment for high-risk acute myeloid leukemia (AML) in patients aged 59 or younger. The goal is to see if newer regimens, including venetoclax and liposome formulations, can better shrink cance…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a cementless hip stem hold up in asian patients?
Disease control Recruiting nowResearchers at a Korean hospital are following 210 adults who receive a cementless total hip replacement using the collarless Actis femoral stem. The study focuses on Asian patients, who tend to be younger at surgery and more often need the operation because of lost blood supply …
Sponsor: Seoul National University Bundang Hospital • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New combo pill aims to shrink spleens and ease symptoms in bone marrow cancer
Disease control Recruiting nowThis phase 3 trial tests whether adding pelabresib to the standard drug ruxolitinib works better than ruxolitinib alone for people with myelofibrosis, a type of bone marrow cancer. About 460 adults who have not taken JAK inhibitors before will receive either the combination or a …
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Scientists train immune cells to hunt down mutated blood cancers
Disease control Recruiting nowThis early-phase trial tests a personalized treatment for people with blood cancers like leukemia. Doctors take a patient's own T cells, modify them in the lab to recognize unique cancer mutations, and infuse them back after a short course of chemotherapy. The goal is to see if t…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug afimkibart tested for Long-Term arthritis control
Disease control Recruiting nowThis study is testing the long-term safety and effectiveness of a drug called afimkibart in people with moderate to severe rheumatoid arthritis. Participants have already taken afimkibart in a previous study and will continue taking it. The goal is to see if the drug remains safe…
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Fish oil capsules could ease rare muscle disease
Disease control Recruiting nowThis study tests whether omega-3 fatty acid supplements from fish oil, combined with a healthy diet, can reduce disease activity in adults with dermatomyositis, a rare autoimmune disease causing muscle weakness and skin rashes. About 300 participants will take either fish oil cap…
Phase 2 • Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Could your own bone marrow cells save your hip from collapse?
Disease control Recruiting nowThis study tests whether adding a patient's own concentrated bone marrow cells to a standard hip surgery (core decompression) can prevent the hip ball from collapsing and delay or avoid the need for a hip replacement. It includes 192 adults with early-stage osteonecrosis (before …
Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a new drug ease the joint pain of psoriatic arthritis?
Disease control Recruiting nowThis trial tests an experimental drug called DDY391 in about 220 adults with moderate to severe psoriatic arthritis, a condition that causes joint pain, swelling, and skin patches. Researchers want to see whether DDY391 can reduce joint symptoms better than a placebo and at what …
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Engineered immune cells take on muscle disease
Disease control Recruiting nowThis study tests a one-time treatment called CABA-201, made from a patient's own immune cells, for people with active inflammatory muscle diseases like dermatomyositis. The therapy aims to reset the immune system by targeting and removing certain immune cells. Researchers will ch…
Phase 2/3 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New combo aims to boost transplant success in rare blood cancer
Disease control Recruiting nowThis study tests whether giving a chemotherapy drug (decitabine) plus a targeted therapy (ruxolitinib, fedratinib, or pacritinib) before a stem cell transplant helps people with advanced myeloproliferative neoplasms (MPN) get to transplant and have better outcomes. About 25 adult…
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Hope for scleroderma: new pill aims to halt disease progression
Disease control Recruiting nowThis Phase 3 trial tests whether the oral drug nerandomilast can slow disease progression in adults with systemic sclerosis (scleroderma). About 448 participants will be randomly assigned to receive either nerandomilast or a placebo twice daily for up to 4 years. Researchers will…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New pill could ease psoriatic arthritis without biologics
Disease control Recruiting nowThis Phase 3 study tests whether the oral drug zasocitinib (TAK-279) can improve symptoms of active psoriatic arthritis in people who have never used biologic treatments. About 1,088 adults will receive either zasocitinib, an active comparator, or a placebo for up to 60 weeks. Th…
Phase 3 • Sponsor: Takeda • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Engineered t cells target hidden leukemia cells in new trial
Disease control Recruiting nowThis phase I trial tests a new treatment for adults with acute myeloid leukemia (AML) who have minimal residual disease (MRD) — small amounts of cancer cells that remain after standard therapy. The treatment uses the patient's own T cells, genetically modified to recognize a prot…
Phase 1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New antibody tested to tame childhood arthritis and cut steroid use
Disease control Recruiting nowResearchers are testing an experimental drug called GenaKumab in children and teens with active systemic juvenile idiopathic arthritis, a condition that causes joint inflammation and recurring fevers. The trial enrolls about 290 participants aged 2 to under 18 who have had sympto…
Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Experimental drug plus radiation shows promise for rare sarcoma
Disease control Recruiting nowThis early-phase trial is testing whether the drug abemaciclib, when given with radiation therapy before surgery, can safely shrink high-risk retroperitoneal liposarcomas. About 18 adults with this rare cancer will receive the combination to find the best dose and check for side …
Phase 1 • Sponsor: University of Washington • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Could a new drug combo beat standard chemo for kids with AML?
Disease control Recruiting nowThis large phase 3 trial is testing whether a new formulation of two chemotherapy drugs (CPX-351) and a targeted drug called gilteritinib can improve outcomes for children and young adults with newly diagnosed acute myeloid leukemia (AML). The study compares these new approaches …
Phase 3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New lupus pill enters Mid-Stage trial – hope for better control?
Disease control Recruiting nowThis study tests an experimental oral drug called BI 3000202 in 405 adults with moderate to severe systemic lupus erythematosus (SLE). Participants are randomly assigned to one of four doses of the drug or a placebo, taken daily for a year alongside their usual lupus treatments. …
Phase 2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New shot could ease skin tightening in rare disease
Disease control Recruiting nowThis study tests an experimental drug called efgartigimod PH20 SC in adults with systemic sclerosis, a disease that causes skin thickening and organ problems. About 81 participants will receive either the drug or a placebo as a shot under the skin for up to 48 weeks. Researchers …
Phase 2 • Sponsor: argenx • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat lupus
Disease control Recruiting nowThis early-phase trial tests a new type of cell therapy called BCMA-CD19-IL-15/IL15sushi compound CAR T cells in 20 people with severe lupus that hasn't improved with standard treatments. The therapy aims to reset the immune system by targeting and eliminating faulty immune cells…
Phase 2 • Sponsor: iCell Gene Therapeutics • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New combo attack on stubborn leukemia: chemo then transplant
Disease control Recruiting nowThis early-phase trial tests a two-step approach for people with acute myeloid leukemia or related blood cancers that have returned or not responded to treatment. First, patients receive intensive chemotherapy (CLAG-M or FLAG-Ida) followed immediately by a reduced-intensity stem …
Phase 1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Hope for kids with leukemia: new drug combo aims to boost remission
Disease control Recruiting nowThis phase 2 trial tests whether adding the targeted drug venetoclax to standard chemotherapy is safe and effective for children and young adults (up to age 22) with newly diagnosed acute myeloid leukemia (AML). The study aims to see if this combination can reduce the amount of c…
Phase 2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New triple therapy aims to boost survival in frail AML patients
Disease control Recruiting nowThis phase 3 trial will test whether adding the drug quizartinib to the standard two-drug combination (venetoclax and azacitidine) helps adults with newly diagnosed acute myeloid leukemia (AML) live longer. The study includes 376 people aged 18 and older who cannot receive intens…
Phase 3 • Sponsor: PETHEMA Foundation • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for myelofibrosis patients: experimental pill targets resistant disease
Disease control Recruiting nowThis early-stage study tests an experimental oral drug, AJ1-11095, in about 76 adults with myelofibrosis (a type of bone marrow cancer) whose disease has stopped responding to standard JAK2 inhibitor therapy. The main goals are to check the drug's safety, find the best dose, and …
Phase 1 • Sponsor: Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a malaria drug help sarcoidosis patients ditch steroids?
Disease control Recruiting nowThis study tests if hydroxychloroquine, a drug used for malaria and autoimmune diseases, can help people with sarcoidosis reduce or stop taking steroids. Sarcoidosis causes inflammation, often in the lungs, but this trial focuses on cases affecting the skin, eyes, or bones. 140 a…
Phase 4 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Could everyday heart drugs shield cancer patients from Radiation's cardiac toll?
Disease control Recruiting nowThis study tests whether two common heart medications—atorvastatin (a statin) and lisinopril (an ACE inhibitor)—can prevent or reduce heart damage caused by radiation therapy for chest cancers like breast, lung, and esophageal cancer. About 60 adults receiving chest radiation wil…
Phase 2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New lupus shot aims to tame flares in phase 2 trial
Disease control Recruiting nowThis phase 2 trial tests a new drug called SG301, given as a shot under the skin, for people with systemic lupus erythematosus (SLE). About 120 participants whose lupus is not well controlled by standard treatments will receive either SG301 or a placebo over several months. The g…
Phase 2 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New combo aims to shrink spleen and boost transplant success in myelofibrosis
Disease control Recruiting nowThis study tests whether giving high-dose ruxolitinib and busulfan before a stem cell transplant can reduce spleen size and help the transplant work better in people with myelofibrosis. About 30 adults aged 18 to 75 with an enlarged spleen and a matched donor will take part. The …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for tough leukemias: experimental pill targets genetic weakness
Disease control Recruiting nowThis study tests an oral drug called revumenib in people with certain types of leukemia that have relapsed or not responded to standard therapy. The trial has two parts: first, finding the best dose, then testing that dose in four groups based on leukemia type. About 447 particip…
Phase 1/2 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for AML patients: quizartinib maintenance trial launches
Disease control Recruiting nowThis study tests two different doses of the drug quizartinib as a maintenance therapy for adults with a specific type of acute myeloid leukemia (FLT3-ITD positive) who are in their first complete remission after initial treatment and have not had a stem cell transplant. The goal …
Phase 2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a heart drug tame rheumatoid arthritis?
Disease control Recruiting nowThis trial tests whether nicorandil, a drug currently used for heart conditions, can reduce disease activity and symptoms in people with rheumatoid arthritis. About 70 adults with moderate-to-severe RA will take either nicorandil or a placebo twice daily for three months, while c…
Phase 2/3 • Sponsor: Ain Shams University • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for leukemia patients who failed standard treatments
Disease control Recruiting nowThis study tests a drug called ponatinib in 50 adults with chronic myeloid leukemia (CML) whose cancer did not respond to or they could not tolerate other targeted therapies. The goal is to see if ponatinib can control the disease by blocking a protein that helps cancer cells gro…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Engineered t cells take aim at stubborn leukemias in early trial
Disease control Recruiting nowThis early-phase study tests a new type of immune therapy for people with certain blood cancers (leukemias) that have returned or not responded to standard treatments. The therapy uses the patient's own T cells, which are modified in the lab to recognize and attack cancer cells c…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug aims to halt lung damage in autoimmune patients
Disease control Recruiting nowThis study tests whether the drug nerandomilast can slow lung scarring in people with autoimmune diseases like rheumatoid arthritis or scleroderma. About 400 adults whose lung function hasn't improved with standard treatment will take either nerandomilast or a placebo twice daily…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug duo aims to halt rare cancer's growth
Disease control Recruiting nowThis study tests whether combining two drugs, mirdametinib and palbociclib, can safely slow or stop advanced liposarcoma (a rare soft-tissue cancer). About 54 adults with liposarcoma that has spread or cannot be removed will receive different doses to find the best one. The main …
Phase 1/2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Promising new combo tackles tough leukemia
Disease control Recruiting nowThis study tests a new mix of drugs for people newly diagnosed with a specific type of acute myeloid leukemia (AML). The treatment combines a targeted drug (venetoclax) with two chemotherapy drugs, then switches to another chemo drug plus venetoclax. The goal is to see if this ap…
Phase 2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Promising new combo therapy for infant leukemia shows potential
Disease control Recruiting nowThis study tests whether adding two targeted drugs, blinatumomab and venetoclax, to standard chemotherapy can improve outcomes for infants with a type of leukemia called acute lymphoblastic leukemia (ALL). About 153 infants will participate. The goal is to see if these combinatio…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug hopes to ease rare muscle diseases
Disease control Recruiting nowThis Phase 3 trial tests a drug called dazukibart in people with active dermatomyositis or polymyositis, rare diseases that cause muscle weakness and inflammation. About 318 adults will receive either the drug or a placebo by IV every 4 weeks for 48 weeks. The study aims to see i…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New transplant recipe targets tough leukemia
Disease control Recruiting nowThis study is for people with a high-risk type of leukemia called CMML. It tests a stronger chemotherapy combination (including thiotepa) given before a stem cell transplant from a donor. The goal is to see if this approach helps patients live longer without the cancer coming bac…
Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for cancer patients with autoimmune conditions: immune checkpoint inhibitor trial expands access
Disease control Recruiting nowThis study is for people who have both an autoimmune disease (like rheumatoid arthritis, lupus, or multiple sclerosis) and an advanced cancer that has spread or cannot be removed by surgery. It tests the safety and effectiveness of the immunotherapy drug nivolumab, given alone or…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for rare blood cancer: experimental drug targets mast cells
Disease control Recruiting nowThis study tests an experimental drug called CGT9486 (bezuclastinib) in people with advanced systemic mastocytosis, a rare and serious blood disorder. The drug aims to control the disease by blocking a key protein that drives abnormal mast cell growth. About 140 adults with aggre…
Phase 2 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for AML patients: Triple-Drug combo targets Tough-to-Treat leukemia
Disease control Recruiting nowThis study tests whether adding pivekimab sunirine to the standard drugs venetoclax and azacitidine helps adults with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. About 660 participants will be randomly assigned to receive ei…
Phase 2/3 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Immune cells harvested from tumors could fight advanced cancers
Disease control Recruiting nowThis early-stage trial tests a personalized cell therapy called lifileucel for people with advanced uveal melanoma (a rare eye cancer) or certain sarcomas (connective tissue cancers). The treatment involves removing immune cells from the patient's tumor, growing them in a lab, an…
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug AZD5492 tested for autoimmune diseases in first human study
Disease control Recruiting nowThis Phase 1 trial tests the safety and tolerability of a new drug called AZD5492 in 72 adults with lupus, myositis, or rheumatoid arthritis. Participants receive one or two doses under the skin and are monitored for side effects and how the drug moves through the body. The study…
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug trial hopes to thicken skin Disease's fate
Disease control Recruiting nowThis study tests an experimental drug called MTX-474 in 85 people with diffuse cutaneous systemic sclerosis, a condition that causes skin thickening and organ damage. Participants will receive either MTX-474 or a placebo for 24 weeks to see if the drug safely reduces skin thickne…
Phase 2 • Sponsor: Mediar Therapeutics • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for kids with tough leukemia: chemo combo trial launches
Disease control Recruiting nowThis early-phase trial is testing a combination of two drugs—Hyper-CVAD chemotherapy and venetoclax—in 22 children and young adults whose leukemia has returned or not responded to treatment. The main goal is to find a safe dose and monitor side effects. If the combination proves …
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug aims to cut blood transfusions for bone marrow disease patients
Disease control Recruiting nowThis study tests an experimental drug called DISC-0974 in about 150 adults with myelofibrosis or myelodysplastic syndrome (MDS) who also have anemia. The goal is to see if the drug can reduce the need for blood transfusions and increase red blood cell levels. The study is in earl…
Phase 1/2 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Could a simple injection dissolve painful calcium lumps in rare diseases?
Disease control Recruiting nowThis study tests whether injecting sodium thiosulfate directly into abnormal calcium deposits can shrink them and reduce pain. It includes people with three rare conditions: systemic sclerosis, dermatomyositis, and a genetic disorder called iPPSD2. Participants receive up to 11 i…
Phase 2 • Sponsor: University Hospital, Limoges • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can a new oral drug take on hard-to-treat leukaemia?
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called AMX-883, taken by mouth, for people with acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS) that has come back or not responded to standard treatments. The study will first test AMX-883 alone, th…
Phase 1 • Sponsor: Amphista Therapeutics Ltd • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New pill could ease severe childhood arthritis
Disease control Recruiting nowThis study tests a new oral medication, upadacitinib, in children aged 1 to 17 with active systemic juvenile idiopathic arthritis (sJIA), a rare and serious form of arthritis that can affect the whole body. About 90 participants will receive either upadacitinib or the standard in…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Double donor transplant trial aims to boost survival in blood cancer patients
Disease control Recruiting nowThis study tests whether using stem cells from both a half-matched family donor and a cord blood donor can improve survival without cancer returning. It is for people with certain high-risk blood cancers like leukemia or myelodysplastic syndromes. The approach aims to control the…
Phase 2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug takes aim at Treatment-Resistant leukemia
Disease control Recruiting nowResearchers are comparing olverembatinib, an experimental drug, with bosutinib, an approved drug, in adults with chronic phase chronic myeloid leukemia (CML-CP). The trial enrolls patients whose disease has not responded well to at least two prior targeted treatments. A separate …
Phase 3 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can a monthly antibiotic shot keep kids with leukemia safer from infections?
Disease control Recruiting nowThis early-phase trial is testing whether a long-acting antibiotic called dalbavancin, given once every 28 days along with a short course of oral antibiotics, can prevent serious bloodstream infections in children and young adults with high-risk leukemia. The study will enroll 29…
Phase 1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Engineered immune cells take on lupus kidney disease
Disease control Recruiting nowThis phase 2 trial is testing a new treatment called FT819 for people with lupus nephritis, a serious kidney complication of lupus. FT819 is made from donor immune cells that are engineered to target and destroy faulty B cells. The study will enroll 53 participants and aims to se…
Phase 2 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New antibody cocktail takes on tough lupus kidney disease
Disease control Recruiting nowThis early-stage trial is testing two experimental drugs, vonsetamig and odronextamab, in people with lupus nephritis that has not responded to standard treatments. The main goal is to check safety and side effects over the long term. Researchers will also see if the drugs can he…
Phase 1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New pill takes on tough blood cancers in early trial
Disease control Recruiting nowThis early-stage study tests an oral drug called AUTX-703 in 34 adults with relapsed or hard-to-treat acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The main goal is to check safety and find the right dose. It's an open-label trial, meaning everyone knows they'r…
Phase 1 • Sponsor: Auron Therapeutics, Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for young AML patients: targeted drug combo tested in phase 2 trial
Disease control Recruiting nowThis study tests two different drug combinations for younger adults with a specific type of acute myeloid leukemia (CBF-AML). One group gets standard chemotherapy plus a targeted antibody, while the other gets the same chemotherapy plus a newer targeted pill. The goal is to see w…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug tulisokibart aims to ease psoriatic arthritis pain
Disease control Recruiting nowThis study tests a new medicine called tulisokibart for people with active psoriatic arthritis, a condition causing joint pain and skin plaques. Researchers will compare different doses of the drug to a placebo in 140 adults to see if it improves symptoms like joint tenderness an…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New targeted drug shows promise for Hard-to-Treat blood cancers
Disease control Recruiting nowThis study is testing a new drug called BGB-11417 (sonrotoclax) in people with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or related blood cancers. The drug works by blocking a protein that helps cancer cells survive. The trial will give the drug alone or toge…
Phase 1/2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug combo aims to boost chemoradiation for head and neck cancer
Disease control Recruiting nowThis early-phase study tests whether adding the experimental drug ipatasertib to standard chemotherapy and radiation is safe and effective for people with advanced head and neck cancer. Ipatasertib may help stop cancer cell growth. About 46 participants will receive the combinati…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New immune cell therapy aims to stop blood cancer relapse after transplant
Disease control Recruiting nowThis early-phase trial tests whether giving patients a special infusion of donor immune cells (with certain T and B cells removed) after a stem cell transplant is safe and can help prevent their blood cancer from coming back. The study enrolls high-risk patients with hard-to-trea…
Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug combo targets tough leukemia in phase II trial
Disease control Recruiting nowThis phase II study is testing a combination of two drugs, enasidenib and azacitidine, in people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The trial enrolls 50 adults with a specific IDH2 gene mutation. The goal is to see if the combinati…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug aims to limit heart damage after major attack
Disease control Recruiting nowThis study tests a medicine called Xolatryp in adults who have had a severe heart attack (STEMI) and are getting a procedure to open blocked arteries. Participants receive either a single 6-hour infusion of Xolatryp or a placebo, and their heart health is monitored for 30 days. T…
Phase 2 • Sponsor: Nyrada Pty Ltd • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for rare blood cancer: targeted drug enters final testing
Disease control Recruiting nowThis study tests a new drug, INCA033989, against the best current treatments for people with a rare blood cancer called essential thrombocythemia who have a specific gene mutation (CALR). About 426 adults who have already tried at least one prior therapy will be randomly assigned…
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
A balloon that coats heart arteries in drug, no stent left behind
Disease control Recruiting nowResearchers are testing whether a balloon catheter coated with the drug sirolimus can safely open narrowed coronary arteries in adults with heart disease. The balloon inflates to press the drug into the artery wall, aiming to keep the vessel open without leaving a permanent stent…
Sponsor: Tonic Medical, Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug ABBV-519 enters first human tests for lupus and arthritis
Disease control Recruiting nowThis early-stage study tests a single dose of ABBV-519 in 30 adults with moderate lupus or rheumatoid arthritis. Researchers will check how the drug moves through the body, how it affects immune cells, and whether it is safe. Participants will be followed for about a year to moni…
Phase 1 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug MK-1045 enters early human testing for lupus and RA
Disease control Recruiting nowThis early study tests a new medicine, MK-1045, in about 21 people with lupus or rheumatoid arthritis. The main goal is to see if it is safe and tolerable at different dose levels. Participants receive the drug through an IV infusion, and researchers monitor for side effects.
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug tested to protect fertility in women with rare tumors
Disease control Recruiting nowThis study tests the drug nirogacestat in 50 premenopausal women with desmoid tumors (a type of non-cancerous but aggressive growth). The main goal is to see if the drug affects ovarian function, such as menstrual periods and hormone levels. Participants take nirogacestat orally,…
Phase 4 • Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug cocktail targets tough blood cancers
Disease control Recruiting nowThis study tests a combination of three drugs—ivosidenib, venetoclax, and azacitidine—in people with blood cancers like acute myeloid leukemia (AML) that have a specific IDH1 mutation. The goal is to see if the combo is safe and works better than current treatments. About 96 adul…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New pill could ease lupus skin rashes in major trial
Disease control Recruiting nowThis study tests a drug called enpatoran for people with lupus who have active skin rashes or lesions. About 202 participants will take either enpatoran or a placebo twice daily for 24 weeks, alongside their usual treatments. The goal is to see if the drug can significantly impro…
Phase 3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for tough leukemia? early trial of debio 1562M begins
Disease control Recruiting nowThis early-phase trial is testing a new drug called Debio 1562M in about 134 people with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The study first checks safety and finds the right dose, then looks at whether the drug can shrink the can…
Phase 1/2 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Could a lower dose of a transplant drug be better for blood cancer patients?
Disease control Recruiting nowThis study is testing whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant, can prevent graft-versus-host disease (a common complication where donor cells attack the patient's body) while still being effective. The trial involves 260 adults with b…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug duo targets tough blood cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called rezatapopt combined with the standard drug azacitidine in 24 adults with a specific type of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has a TP53Y220C mutation. The main goal is to check safety and find the b…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug combo targets tough blood cancers
Disease control Recruiting nowThis phase 2 trial tests a drug called olutasidenib combined with other targeted therapies for people with relapsed or hard-to-treat blood cancers that have a specific IDH1 mutation plus other signaling mutations. The study aims to see how safe and tolerable these drug combinatio…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New cord blood transplant recipe aims to beat tough blood cancers
Disease control Recruiting nowThis study tests a standardized, optimized approach to cord blood transplantation for adults with high-risk blood cancers like leukemia and lymphoma. The method includes specific chemotherapy, radiation, and stem cell dosing, followed by careful monitoring. Researchers hope to im…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New pill aims to calm lupus skin flares in major trial
Disease control Recruiting nowThis study tests an experimental pill called enpatoran for people with lupus who have active skin rashes. About 202 participants will receive either the drug or a placebo for 24 weeks, while continuing their usual treatments. The goal is to see if enpatoran can significantly redu…
Phase 3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New hope for psoriatic arthritis sufferers: experimental drug sonelokimab enters final testing phase
Disease control Recruiting nowThis study tests a new drug called sonelokimab for adults with active psoriatic arthritis who have not improved with or cannot take standard TNF-blocker medications. About 600 participants will receive either sonelokimab, a placebo, or an existing drug (risankizumab) for comparis…
Phase 3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New pill aims to keep blood cancer away after transplant
Disease control Recruiting nowThis study tests a daily pill called olutasidenib given after a stem cell transplant to people with certain blood cancers (like AML or MDS) that have an IDH1 mutation. The goal is to see if the drug is safe and tolerable as maintenance therapy. About 31 participants will take the…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New combo aims to boost lung cancer treatment in patients with bone metastases
Disease control Recruiting nowThis phase 2 trial tests whether adding the drug narlumosbart and precise radiation therapy to standard first-line treatment can help people with advanced non-small cell lung cancer that has spread to the bones. The study will enroll 27 adults who have not had prior systemic ther…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New hope for AML patients in india: drug combo aims for remission without intensive chemo
Disease control Recruiting nowThis study tests a combination of two drugs, venetoclax and azacitidine, in about 100 adults in India with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for standard intensive chemotherapy. The goal is to see if the combo can put the cancer into remissio…
Phase 4 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug combination targets Hard-to-Treat blood cancers
Disease control Recruiting nowResearchers are testing an experimental drug called LP-108, a BCL-2 inhibitor, combined with azacitidine in adults with acute myeloid leukemia, myelodysplastic syndromes, or chronic myelomonocytic leukemia. The trial aims to find the highest dose people can tolerate and the best …
Phase 1 • Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug aimed at genetic weakness in blood disorders
Disease control Recruiting nowThis study tests a drug called olutasidenib in people with certain early blood conditions (CCUS, lower-risk MDS, or CMML) that have a specific IDH1 gene change. The goal is to see if the drug can control the disease and is safe. About 15 participants will take the drug and be mon…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New triple therapy targets tough leukemia
Disease control Recruiting nowThis study tests a combination of three drugs—olutasidenib, decitabine, and venetoclax—in people with acute myeloid leukemia (AML) that has a specific IDH1 gene mutation. The goal is to find a safe and effective dose for those whose cancer has returned or not responded to treatme…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Could chemo before surgery beat sarcoma? new trial aims to find out
Disease control Recruiting nowThis study is for people with a rare, high-risk cancer called retroperitoneal sarcoma. It compares two approaches: getting chemotherapy before surgery versus surgery alone. The goal is to see if the chemo-first approach helps prevent the cancer from coming back. About 250 partici…
Phase 3 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New pill shows promise for rare joint tumor in early trial
Disease control Recruiting nowThis phase 2 trial tests a daily oral drug called pimicotinib in 20 Japanese adults with tenosynovial giant cell tumor (TGCT) that cannot be removed by surgery. The study aims to see if the drug is safe, how it moves through the body, and whether it shrinks tumors. Participants t…
Phase 2 • Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Freeze and pill combo takes on rare tumors
Disease control Recruiting nowThis study tests a two-step approach for desmoid tumors, which are non-cancerous but can be painful and grow. First, patients take a daily pill called nirogacestat for three months. Then, one tumor is frozen with a special needle (cryoablation). The goal is to see if this combina…
Phase 2 • Sponsor: Nam Bui • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New antibody therapy targets rare blood cancers in first human trial
Disease control Recruiting nowThis early-stage study tests a new drug called JNJ-88549968, a bispecific antibody designed to direct the body's immune T cells to attack cancer cells with a specific CALR mutation. The trial will enroll about 220 adults with essential thrombocythemia or myelofibrosis who carry t…
Phase 1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New hope for leukemia patients: experimental drug combo enters late-stage trial
Disease control Recruiting nowThis study tests an experimental drug called BL-M11D1 combined with either standard chemotherapy or another targeted therapy in 216 adults newly diagnosed with acute myeloid leukemia (AML). The goal is to see if the combination is safe and works better at controlling the cancer. …
Phase 2/3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Engineered immune cells take on autoimmune diseases in first human trial
Disease control Recruiting nowThis early-stage study tests a new treatment called ALLO-329 for people with lupus, myositis, or scleroderma. The therapy uses specially engineered immune cells from a donor to target and calm the overactive immune system. The main goals are to check safety and see if it can impr…
Phase 1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Promising lupus drug anifrolumab now tested in kids
Disease control Recruiting nowThis phase 3 study tests anifrolumab, a biologic drug given by IV, in 100 children aged 5 to 18 with moderate to severe systemic lupus erythematosus (SLE). Participants continue their standard care and are randomly assigned to receive anifrolumab or a placebo. The goal is to see …
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Nature trails may be a new prescription for foot pain
Disease control Recruiting nowThis trial tests whether walking on uneven nature trails in minimalist shoes can strengthen the small muscles of the foot and reduce pain in people with plantar fasciitis. Researchers will compare this nature-walking routine to a standard approach in healthy adults and those with…
Sponsor: University of Florida • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat lupus
Disease control Recruiting nowThis study tests a new treatment called AZD0120 for people with severe lupus that hasn't improved with standard therapies. AZD0120 is a type of CAR T cell therapy that targets two proteins (CD19 and BCMA) on immune cells to calm the overactive immune system. The trial will enroll…
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New hope for heart lining pain: can CardiolRx keep flare-ups away?
Disease control Recruiting nowThis study tests whether the drug CardiolRx can prevent another episode of pericarditis (inflammation around the heart) in people who have had repeated attacks. About 110 adults who have been stable on an IL-1 blocker for at least a year will stop that medication and receive eith…
Phase 3 • Sponsor: Cardiol Therapeutics Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New lupus drug aims to help patients stop steroids
Disease control Recruiting nowThis study tests a medicine called anifrolumab for people with lupus who have not taken strong immune-suppressing drugs before. The goal is to see if the drug can help patients reach remission and reduce or stop their steroid use. About 245 adults will receive weekly injections f…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Lupus drug continuation trial offers hope for disease control
Disease control Recruiting nowThis study offers continued treatment with deucravacitinib for people with systemic lupus erythematosus (SLE) or related skin lupus who finished earlier trials. It aims to keep the disease under control by providing ongoing access to the medication. Only 35 participants are being…
Phase 4 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New injection aims to heal skin ulcers in rare disease
Disease control Recruiting nowThis phase 2 trial tests an injection called SHR-1139 in 10 adults with ulcerative pyoderma gangrenosum, a rare skin condition that causes painful, open sores. The main goal is to see if the drug can completely close the target ulcer within 12 weeks. Researchers will also check f…
Phase 2 • Sponsor: Shandong First Medical University • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New daily pill shows promise for Long-Term psoriatic arthritis control
Disease control Recruiting nowThis study tests the long-term safety and effectiveness of an oral drug called zasocitinib (TAK-279) in adults with active psoriatic arthritis, a condition causing joint pain and skin patches. About 1,182 participants who completed a one-year parent study will take either a lower…
Phase 3 • Sponsor: Takeda • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Could a targeted pill boost chemo for tough blood cancer?
Disease control Recruiting nowThis Phase 3 trial tests whether adding the drug venetoclax to standard chemotherapy helps adults with newly diagnosed acute myeloid leukemia (AML) or a related high-risk condition. About 650 participants aged 18 to 75 will receive either venetoclax or a placebo alongside chemo. …
Phase 3 • Sponsor: University of Ulm • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a new pill shrink Hard-to-Treat tumors?
Disease control Recruiting nowThis trial is testing an experimental drug called SA53-OS in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by blocking a protein called MDM2, which may help slow or stop tumor growth. The study has two parts: first,…
Phase 1/2 • Sponsor: Lamassu Bio Inc • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for kids with tough leukemia: experimental drug enters human testing
Disease control Recruiting nowThis early-stage study is testing an experimental drug called pivekimab sunirine in about 18 children whose acute myeloid leukemia (AML) has come back or not responded to standard treatments. The main goals are to check the drug's safety and how it moves through the body. Partici…
Phase 1 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat leukemia
Disease control Recruiting nowThis study tests a new treatment for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to standard therapy. The treatment uses specially engineered natural killer (NK) cells designed to recognize and attack cancer cells…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Second chance: vyxeos targets tough leukemia after standard chemo fails
Disease control Recruiting nowThis study tests a drug called Vyxeos in adults with acute myeloid leukemia (AML) whose cancer did not go away after standard chemotherapy. Vyxeos combines two chemo drugs inside a tiny fat bubble (liposome) to deliver them more effectively. The trial will check for side effects …
Phase 1/2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a lupus drug protect lungs in connective tissue disease?
Disease control Recruiting nowThis study looks at the long-term safety and effectiveness of belimumab in adults with lung scarring (interstitial lung disease) caused by systemic sclerosis or other connective tissue diseases. About 514 people who completed earlier trials will receive belimumab for up to severa…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for Still's disease: experimental drug enters Mid-Stage trial
Disease control Recruiting nowThis study tests a new medicine called MAS825 for people with Still's disease, a rare inflammatory condition causing fever, rash, and joint pain. About 20 children and adults with active disease will receive the drug to see if it safely controls symptoms. The goal is to improve d…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug trial aims to tame hardening skin and lung damage in scleroderma
Disease control Recruiting nowThis study tests whether the drug ianalumab can help people with diffuse cutaneous systemic sclerosis, a condition that causes skin thickening and can damage internal organs like the lungs. About 200 adults will receive either ianalumab or a placebo as a shot under the skin. Rese…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New antibody drug takes aim at autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new drug called SAR448501 (DR-0201) in 62 adults with lupus or rheumatoid arthritis. The drug is a bispecific antibody designed to target the immune system. The main goal is to check safety and find the right dose, not yet to prove it works. Partici…
Phase 1 • Sponsor: Sanofi • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug trial aims to control arthritis in kids
Disease control Recruiting nowThis study is testing a drug called secukinumab, given as an IV infusion, in 20 children aged 2 to 17 with juvenile psoriatic arthritis. The main goals are to see how the drug moves through the body and to check its safety over up to 6 years. This is an early-stage trial, so it f…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug combo targets resistant leukemia
Disease control Recruiting nowThis early-stage trial tests a combination of two drugs, gilteritinib and momelotinib, for adults with a specific type of acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goal is to find a safe dose of momelotinib when given with gilteritini…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New pill could ease psoriatic arthritis pain in major trial
Disease control Recruiting nowThis Phase 3 trial tests whether the experimental drug zasocitinib (TAK-279) can reduce joint swelling and pain in people with active psoriatic arthritis. About 600 adults will receive either the drug or a placebo for up to 60 weeks. The main goal is to see if more people on the …
Phase 3 • Sponsor: Takeda • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for heart inflammation sufferers: experimental drug VTX2735 enters Mid-Stage trial
Disease control Recruiting nowThis study tests an experimental drug called VTX2735 in 50 adults with recurrent pericarditis, a condition where the heart's lining becomes inflamed and painful. The goal is to see if the drug is safe and can reduce pain and inflammation. Participants receive different doses over…
Phase 2 • Sponsor: Zomagen Biosciences Ltd. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New antibody GEN3018 enters first human tests for tough blood cancers
Disease control Recruiting nowThis early-stage trial is testing a new antibody drug called GEN3018 in people whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) has come back or stopped responding to treatment. The main goal is to check safety and find the right dose. Up to 78 parti…
Phase 1 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for rare sarcomas: chemo plus immunotherapy combo enters phase III trial
Disease control Recruiting nowThis Phase III trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (doxorubicin) helps people with advanced dedifferentiated liposarcoma or undifferentiated pleomorphic sarcoma live longer without their cancer worsening. About 365 adults whose…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Weight-Loss drug added to arthritis therapy shows promise in new trial
Disease control Recruiting nowThis study looks at whether adding tirzepatide (a weight-loss drug) to standard ixekizumab treatment helps adults with active psoriatic arthritis who are overweight or obese. About 200 participants will receive both medications for up to 12 months. The goal is to see if this comb…
Phase 4 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New shot aims to tame rare autoimmune disease
Disease control Recruiting nowThis early-phase trial tests a new drug called PRO-203, given as a single shot under the skin. First, healthy volunteers will check safety; then, people with systemic sclerosis (a rare autoimmune disease that hardens skin and organs) will receive the drug. The main goal is to see…
Phase 1/2 • Sponsor: Prolium Bioscience, Inc • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New drug cevostamab enters early human testing for lupus
Disease control Recruiting nowThis early-stage trial will test the safety and tolerability of a new drug, cevostamab, in 46 people with systemic lupus erythematosus, some of whom also have active lupus nephritis. The drug is given intravenously, and researchers will monitor side effects and how the drug moves…
Phase 1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New drug could reduce Blood-Letting for polycythemia vera patients
Disease control Recruiting nowThis phase 3 trial tests whether adding the drug sapablursen to standard treatment helps people with polycythemia vera, a blood disorder causing too many red blood cells. About 250 participants who currently need regular blood removal (phlebotomy) will receive either sapablursen …
Phase 3 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New hope for stiff lungs? drug trial targets scarring from autoimmune disease
Disease control Recruiting nowThis phase 3 trial tests whether belimumab (Benlysta) can stabilize or improve lung function in adults with interstitial lung disease caused by connective tissue diseases like rheumatoid arthritis or lupus. About 440 participants will receive either belimumab injections or a plac…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Could a lupus drug help scleroderma lungs?
Disease control Recruiting nowThis study tests whether belimumab (Benlysta), a drug already used for lupus, can improve lung function and skin thickening in adults with scleroderma-related interstitial lung disease. About 300 participants will receive either belimumab or a placebo added to their standard care…
Phase 2/3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Could amniotic membrane ease bladder pain? new trial seeks answers
Disease control Recruiting nowThis study tests whether injecting a substance made from donated amniotic membrane into the bladder can reduce pain and urgency in women with interstitial cystitis (painful bladder syndrome). One hundred women who have not gotten better with other treatments will receive either t…
Phase 2/3 • Sponsor: David Sheyn • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug combo aims to tame rare childhood leukemia
Disease control Recruiting nowThis study tests a combination of two drugs, trametinib and azacitidine, for children newly diagnosed with juvenile myelomonocytic leukemia (JMML), a rare blood cancer. Lower-risk patients get just these two drugs, while higher-risk patients also receive standard chemotherapy. Th…
Phase 1/2 • Sponsor: Therapeutic Advances in Childhood Leukemia Consortium • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for kids with rare cancers: targeted drug repotrectinib enters trial
Disease control Recruiting nowThis study tests a drug called repotrectinib in children and young adults (up to age 25) with advanced solid tumors, lymphoma, or brain tumors that have specific gene changes (ALK, ROS1, or NTRK1-3). The goal is to find the safest dose and see if the drug shrinks tumors. Particip…
Phase 1/2 • Sponsor: Turning Point Therapeutics, Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Triple drug cocktail targets tough leukemia
Disease control Recruiting nowThis study tests a combination of three drugs—ASTX727, venetoclax, and gilteritinib—for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome that has a FLT3 mutation. The drugs work in different ways to stop cancer cells from growing. The trial aims to f…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug combo aims to control rare blood cancer in High-Risk patients
Disease control Recruiting nowThis study tests a combination of two drugs, azacitidine and enasidenib, in people with a high-risk blood cancer called myelodysplastic syndrome (MDS) that has a specific genetic change (IDH2 mutation). The goal is to see if the drugs can stop cancer growth and improve outcomes. …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a new drug shrink advanced solid tumors?
Disease control Recruiting nowThis trial tests an experimental drug called DS-2243a in adults with advanced solid tumors, including sarcoma, that have spread or cannot be removed surgically. The study has two parts: first, researchers find the safest dose by giving increasing amounts to small groups; then, th…
Phase 1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Experimental drug combo aims to shrink Hard-to-Treat sarcomas
Disease control Recruiting nowThis early-stage trial tests a combination of two drugs—peposertib and a low-dose form of the chemotherapy doxorubicin—in people with advanced sarcomas that have spread or can't be removed by surgery. The goal is to find the safest dose and see if the combo can shrink tumors or s…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New lupus drug shows promise in major trial
Disease control Recruiting nowThis study tests an experimental drug called dapirolizumab pegol for people with moderate to severe lupus. About 450 participants will receive either the drug or a placebo, added to their usual treatments. The goal is to see if the drug can improve lupus symptoms over 48 weeks.
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Supercharged immune cells take on resistant blood cancers
Disease control Recruiting nowThis study tests a new type of immune cell therapy for people with myeloid cancers (like AML or MDS) that have come back or not responded to treatment. The cells are taken from donated cord blood, engineered to better recognize and attack cancer cells, and given after chemotherap…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Knee surgery for Over-50s: does a specialized ACL technique match younger Patients' results?
Disease control Recruiting nowThis study compares outcomes of a specific ACL reconstruction technique, called over-the-top with lateral extra-articular tenodesis (LET), in patients over 50 years old versus those under 30. The technique uses the patient's own hamstring tendons and adds an extra procedure to st…
Sponsor: Stefano Zaffagnini • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for kids with tough leukemia: oral drug combo enters human testing
Disease control Recruiting nowThis early-phase trial is testing a combination of two oral drugs—venetoclax and decitabine/cedazuridine—in children and teens whose acute myeloid leukemia (AML) has returned or not responded to prior treatment. The study aims to find the safest dose and check for early signs tha…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a new pill rescue patients when standard leukemia drugs stop working?
Disease control Recruiting nowThis phase 3 trial tests the drug radotinib in adults with chronic-phase chronic myeloid leukemia (CML) who have not responded to or could not tolerate earlier treatments such as imatinib. Participants take radotinib twice daily, and researchers measure how well it reduces leukem…
Phase 3 • Sponsor: Il-Yang Pharm. Co., Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for kids with tough leukemias: experimental combo trial opens
Disease control Recruiting nowThis phase 1 study is testing a combination of three drugs—ziftomenib, venetoclax, and azacitidine—in children and young adults (ages 2 to 21) with acute leukemia that has returned or not responded to treatment. The main goal is to find the safest dose of ziftomenib when given wi…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New pill plus chemo shows promise for kids with tough cancers
Disease control Recruiting nowThis study tests an experimental pill called silmitasertib combined with standard chemotherapy in children and young adults (under 30) whose solid tumors (like neuroblastoma, Ewing sarcoma, or osteosarcoma) have come back or not responded to treatment. The goal is to find a safe …
Phase 1/2 • Sponsor: Milton S. Hershey Medical Center • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New study tests ilaris to tame rare inflammatory disease
Disease control Recruiting nowThis study looks at how well and how safely the drug Ilaris (canakinumab) works for people with Schnitzler's syndrome, a rare condition that causes hives, fever, joint pain, and fatigue. About 5 participants will receive the drug and be monitored for up to 48 weeks. The goal is t…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New CML drug asciminib under Real-World study
Disease control Recruiting nowThis study is watching how well asciminib works and how safe it is in adults with a type of blood cancer called chronic myeloid leukemia. It includes people who are newly diagnosed or have already tried one other treatment. The main goal is to see how many patients reach a very l…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Experimental drug plus radiation aims to tackle returning head and neck cancers
Disease control Recruiting nowThis early-phase trial is testing whether a drug called camonsertib, combined with a precise type of radiation, can help control head and neck cancers that have come back or cannot be removed by surgery. About 39 adults with these cancers will receive the drug along with focused …
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Could less be more? new trial shortens leukemia drug course for seniors
Disease control Recruiting nowThis study looks at whether giving the drug venetoclax for a shorter time, along with the combination drug ASTX727, works as well as the usual longer course for adults aged 60 and older with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for strong chemot…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a new pill shrink the spleen in myelofibrosis?
Disease control Recruiting nowThis early-stage trial tests an experimental pill called WJ01024 in people with myelofibrosis, a bone marrow disorder that often causes an enlarged spleen. The study has two parts: one gives WJ01024 alone to patients whose previous JAK inhibitor treatment stopped working, and the…
Phase 1 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug takes aim at autoimmune diseases in early human test
Disease control Recruiting nowThis early-stage study tests an experimental drug called LY4298445 in healthy volunteers and people with lupus or rheumatoid arthritis. The main goal is to check safety and how the body handles the drug. Participants will receive either the drug or a placebo, and the study lasts …
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Could fewer pills mean same relief for rheumatoid arthritis?
Disease control Recruiting nowThis trial tests whether people with rheumatoid arthritis who have stable disease can stop taking methotrexate or leflunomide while continuing their TNF inhibitor, restarting the drug if needed. Researchers compare this approach to staying on the combination therapy. They track d…
Phase 4 • Sponsor: Sint Maartenskliniek • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Genetic roadmap guides new hope for tough leukemia
Disease control Recruiting nowThis study screens people with acute myeloid leukemia (AML) for specific genetic markers to assign them to a treatment sub-study with a targeted drug or combination. It aims to improve response rates by personalizing therapy based on each person's cancer profile. The trial enroll…
Phase 2/3 • Sponsor: Beat AML, LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug combo hopes to improve myelofibrosis treatment
Disease control Recruiting nowThis early-phase trial is testing whether adding abemaciclib to the standard drug ruxolitinib is safe and effective for people with myelofibrosis, a type of bone marrow cancer. The study will enroll 18 adults who have been on ruxolitinib for at least 12 weeks. Researchers will mo…
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for kids with psoriatic arthritis: apremilast trial begins
Disease control Recruiting nowThis Phase 3 study tests whether the drug apremilast (Otezla) can safely reduce joint inflammation and pain in children aged 5 to 17 with active juvenile psoriatic arthritis. About 60 participants will receive either apremilast or a placebo pill for 16 weeks. The main goal is to …
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Could vitamin d ease sarcoidosis? new trial investigates
Disease control Recruiting nowThis study looks at whether vitamin D supplements can help people with sarcoidosis who have low vitamin D levels. Researchers will give some participants vitamin D2 and others a placebo, then measure changes in lung function and quality of life. The goal is to see if correcting v…
Phase 4 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for Hard-to-Treat blood cancers: SLS009 trial launches
Disease control Recruiting nowThis study tests a new drug called SLS009, alone or with other medicines, in people with blood cancers like leukemia and lymphoma that have come back or not responded to treatment. It also includes newly diagnosed patients with high-risk leukemia. The goal is to see if the drug i…
Phase 1/2 • Sponsor: Sellas Life Sciences Group • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for AML patients who fail venetoclax?
Disease control Recruiting nowThis pilot study tests the drug olutasidenib, with or without azacitidine, in 25 adults with a specific type of acute myeloid leukemia (IDH1-mutated) that has returned or not responded after venetoclax treatment. The goal is to see if the cancer can be brought into remission. Par…
Phase 2 • Sponsor: Timothy Pardee • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug combo aims to stop blood cancer relapse after transplant
Disease control Recruiting nowThis study tests whether adding the targeted drug venetoclax to standard chemotherapy before a stem cell transplant can help prevent cancer from returning in people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). About 138 participants aged 12 to 6…
Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a single cell therapy calm multiple autoimmune diseases?
Disease control Recruiting nowThis trial tests an investigational cell therapy called FT839 in people with active autoimmune diseases, including ANCA-associated vasculitis, inflammatory myositis, rheumatoid arthritis, lupus, and systemic sclerosis. Participants receive FT839 as two intravenous infusions, some…
Phase 1/2 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug hopes to heal painful skin ulcers in rare disease
Disease control Recruiting nowThis study tests whether spesolimab, given as an infusion, can help close skin ulcers in adults with pyoderma gangrenosum, a rare inflammatory skin condition. About 90 participants will receive either spesolimab or a placebo, along with corticosteroids. The trial lasts about 1.5 …
Phase 3 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a targeted pill boost standard therapy for hard-to-treat leukemia?
Disease control Recruiting nowThis phase 3 trial is testing whether adding revumenib, a drug that blocks a protein called menin, to the usual two-drug combination (azacitidine and venetoclax) can improve outcomes for adults newly diagnosed with acute myeloid leukemia (AML) that has a specific genetic change (…
Phase 3 • Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New trial aims to find safer chemo for stem cell transplants in leukemia patients
Disease control Recruiting nowThis study tests two chemotherapy drugs, treosulfan and melphalan, given before a stem cell transplant in 220 adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to see which drug works better at helping patients survive longer with fewer side …
Phase 2 • Sponsor: Technische Universität Dresden • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New hope for kids with leukemia: drug trial targets cancer control
Disease control Recruiting nowThis study tests a drug called asciminib in children aged 1 to 18 with a specific leukemia (Ph+ CML-CP). The goal is to see if the drug can control the cancer by reducing the number of cancer cells. About 50 children will take the drug, and researchers will check how well it work…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New pill combo offers hope for older leukemia patients who Can't handle chemo
Disease control Recruiting nowThis study tests whether taking two oral medications (decitabine and ivosidenib) together can control acute myeloid leukemia (AML) in patients aged 60+ or those too frail for standard chemo. About 50 participants will take the pills in 28-day cycles until the disease worsens or s…
Phase 2 • Sponsor: PETHEMA Foundation • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a new drug pair beat standard chemotherapy for tough AML?
Disease control Recruiting nowThis trial tests whether the combination of venetoclax and azacytidine works better than the standard chemotherapy regimen of daunorubicin plus cytarabine in adults aged 18 to 64 with newly diagnosed acute myeloid leukemia that has adverse risk features. Participants are randomly…
Phase 2/3 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Experimental CAR t therapy takes on tough leukemia
Disease control Recruiting nowThis early-phase trial tests a new treatment called CD64 CAR T cells for adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to target and attack leukemia cells. The m…
Phase 1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug aims to cut blood removal in rare cancer
Disease control Recruiting nowThis trial tests rusfertide, an injected drug, in Japanese adults with polycythemia vera, a rare blood cancer that causes too many red blood cells. The goal is to see if rusfertide can keep red blood cell levels under control and reduce the need for phlebotomy (blood removal). Al…
Phase 2 • Sponsor: Takeda • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New pill aims to ease psoriatic arthritis pain
Disease control Recruiting nowThis study tests a new drug called TQH3906 for people with active psoriatic arthritis, a condition causing joint pain and skin patches. About 156 adults will receive either TQH3906, a placebo, or an existing drug (tofacitinib) for 12 weeks. The main goal is to see if TQH3906 impr…
Phase 2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug cocktail aims to tame deadly transplant complication
Disease control Recruiting nowThis study tests whether adding the drug ruxolitinib to standard medications (cyclophosphamide and tacrolimus) can prevent severe graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers like leukemia. About 124 adults will receive the drug com…
Phase 2 • Sponsor: Hannah Choe, MD • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New combo aims to fight relapsed leukemia after transplant
Disease control Recruiting nowThis study tests a combination of a PD-1 inhibitor (camrelizumab), a chemotherapy drug (azacitidine), and donor immune cells (DLI) in 43 adults with acute myeloid leukemia that has returned after a stem cell transplant. The goal is to see if this approach can help patients achiev…
Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New lupus drug cizutamig enters early human safety trials
Disease control Recruiting nowThis early-stage study is testing a new drug called cizutamig in about 47 adults with systemic lupus erythematosus (SLE), a chronic autoimmune disease. The main goal is to check if the drug is safe and tolerable, and to see how it moves through the body. Participants must have ac…
Phase 1 • Sponsor: Candid Therapeutics • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New engineered graft aims to improve stem cell transplants for kids with leukemia
Disease control Recruiting nowThis study tests a specially engineered donor graft called Orca-Q in children and young adults with blood cancers who need a stem cell transplant. The graft is designed to help the new cells take hold and reduce complications. The trial is currently on hold, but aims to enroll 40…
Phase 1/2 • Sponsor: University of Florida • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug miRisten targets Tough-to-Treat leukemia in early trial
Disease control Recruiting nowThis early-phase trial is testing a new drug called miRisten in 12 adults whose acute myeloid leukemia (AML) has come back or not responded to prior treatments. The drug works by blocking a molecule that helps cancer cells grow. The main goal is to check safety and find the best …
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug combo aims to tame stubborn psoriatic arthritis
Disease control Recruiting nowThis study tests whether adding deucravacitinib to standard therapy helps adults with psoriatic arthritis that is not well controlled. About 128 participants will receive the combination and be monitored for 48 weeks. The goal is to reduce skin and joint symptoms and improve qual…
Phase 4 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New lupus drug tracked in global real-world study
Disease control Recruiting nowThis study follows 200 adults with lupus who are starting anifrolumab for the first time, to see how well it works in everyday clinics. Researchers will measure disease activity, skin symptoms, fatigue, and quality of life over time. The goal is to provide real-world evidence to …
Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New pill could boost leukemia treatment for patients with specific gene changes
Disease control Recruiting nowThis phase 3 trial tests whether adding the drug bleximenib to standard chemotherapy helps adults with a certain genetic type of acute myeloid leukemia (AML). About 875 people will get either bleximenib or a placebo alongside chemo, then be followed for 4 years. The goal is to se…
Phase 3 • Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for kids with joint pain: risankizumab trial launches
Disease control Recruiting nowThis study tests a drug called risankizumab in children with juvenile psoriatic arthritis, a condition causing joint pain and swelling. About 40 kids will receive either risankizumab or the standard drug adalimumab for 24 weeks, with responders continuing for up to 2 years. The g…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New combo therapy for rare blood cancers put on hold
Disease control Recruiting nowThis phase 2 trial compares a drug combo (ASTX727 plus iadademstat) against ASTX727 alone for people with advanced myeloproliferative neoplasms (MPNs), a group of rare blood cancers. The study aims to see if adding iadademstat improves complete response rates. However, the trial …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a new biologic ease rheumatoid arthritis when standard drugs fail?
Disease control Recruiting nowThis phase 2 trial tests whether telitacicept, an experimental biologic given as a weekly injection, can improve symptoms in people with difficult-to-treat rheumatoid arthritis. Participants receive either telitacicept plus standard therapy or standard therapy alone for 24 weeks.…
Phase 2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New combo therapy targets tough blood cancers
Disease control Recruiting nowThis early-stage trial tests a combination of two drugs, ivosidenib and ruxolitinib, in people with advanced blood cancers (MPNs) that have an IDH1 mutation. The main goal is to find the safest dose and see if the combo helps control the disease. About 18 adults will take part.
Phase 1 • Sponsor: University of Chicago • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New lupus drug anifrolumab put to the test in everyday clinics
Disease control Recruiting nowThis study is tracking 125 adults with lupus who are starting a new drug called anifrolumab, given as a shot under the skin. Researchers want to see how many patients achieve remission (no active disease) after 24 months of treatment in real-world clinics, not just in strict rese…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can an immunotherapy combo shrink sinonasal tumors before surgery?
Disease control Recruiting nowThis trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before surgery can help people with sinonasal cancer, a rare cancer of the nasal cavity and sinuses. Participants receive toripalimab along with carboplatin and docetaxel, then undergo sur…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Vitamin c boost: could high doses help treat a tough blood cancer?
Disease control Recruiting nowThis early-stage trial is testing whether adding high-dose vitamin C (given through an IV) to the usual two-drug combination (azacitidine and venetoclax) is safe and effective for people newly diagnosed with acute myeloid leukemia who cannot handle intensive chemotherapy. About 3…
Phase 1 • Sponsor: Kittika Poonsombudlert • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a helmet or simple repositioning reshape an Infant's head?
Disease control Recruiting nowThis trial tests two ways to correct flat head syndrome in infants: caregiver-led repositioning and a custom-fit helmet. Researchers will measure head shape changes in treated infants and compare them with a group of typically developing infants. Infants with torticollis will als…
Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug combo aims to tackle tough leukemia
Disease control Recruiting nowThis early-phase study tests a new drug called lonitoclax combined with azacitidine in 66 adults whose acute myeloid leukemia has returned or not responded to prior treatment. The main goal is to find a safe dose and check for early signs that the combination might help control t…
Phase 1 • Sponsor: Lomond Therapeutics Holdings, Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a targeted drug combo replace harsh chemo for NPM1 leukemia?
Disease control Recruiting nowThis trial tests whether a combination of venetoclax and azacitidine can work as well as or better than standard intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia that has an NPM1 mutation. Participants are aged 18 to 70 and healthy enough for intensiv…
Phase 2 • Sponsor: Technische Universität Dresden • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a pill calm the skin symptoms of sarcoidosis?
Disease control Recruiting nowThis trial investigates whether an oral medication called brepocitinib can safely reduce skin lesions in adults with cutaneous sarcoidosis, a condition where inflammation causes bumps and rashes on the skin. Participants will receive either brepocitinib or a placebo to compare ef…
Phase 2/3 • Sponsor: Priovant Therapeutics, Inc. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can two cancer drugs team up to slow a rare sarcoma?
Disease control Recruiting nowThis phase 2 trial tests whether combining pemigatinib, an FGFR inhibitor, with retifanlimab, a PD-1 inhibitor, can slow tumor growth in people with advanced dedifferentiated liposarcoma (DDLPS), an aggressive soft tissue cancer. The study enrolls adults whose disease has progres…
Phase 2 • Sponsor: Lund University Hospital • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a pill plus injection tame a tough blood cancer?
Disease control Recruiting nowThis study looks at how well a combination of two drugs—venetoclax (a pill) and azacitidine (an injection)—works for adults newly diagnosed with acute myeloid leukemia (AML), a cancer of the blood and bone marrow. The participants are people who are older or have health issues th…
Sponsor: AbbVie • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a targeted pill keep leukemia from returning after transplant?
Disease control Recruiting nowThis phase II trial is testing whether the drug ivosidenib, taken as a pill, can help prevent relapse in people with acute myeloid leukemia (AML) or myelodysplastic neoplasia (MDS) who have an IDH1 mutation and have recently undergone a stem cell transplant. Participants will sta…
Phase 2 • Sponsor: Technische Universität Dresden • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New drug aims to ease anemia in bone marrow cancer patients
Disease control Recruiting nowThis Phase 3 trial tests whether elritercept can improve anemia in people with myelofibrosis who are already taking ruxolitinib. About 324 participants will receive either elritercept or a placebo for at least 9 months. The main goal is to see if the drug reduces the need for red…
Phase 3 • Sponsor: Takeda • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Lupus drug trial aims for remission without daily pills
Disease control Recruiting nowThis study tests a drug called mosunetuzumab in 30 people with lupus, a disease where the immune system attacks the body. The goal is to see if the drug can put lupus into remission so that participants can stop most lupus medications for at least 6 months. However, some people m…
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can a tropical tea shrink blood cancers?
Disease control Recruiting nowThis pilot study tests whether drinking tea made from soursop leaves can reduce the number of cancer cells in people with relapsed or refractory acute myeloid leukemia (AML) or multiple myeloma (MM) — blood cancers that have not responded to standard treatments. About 20 particip…
Early phase 1 • Sponsor: Roger Strair • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Can bone marrow stem cells calm lupus kidney flares?
Disease control Recruiting nowThis trial tests whether a single intravenous dose of mesenchymal stem cells, derived from bone marrow, can safely help adults with active lupus nephritis achieve a complete or partial kidney response. Participants receive either the stem cells or a placebo (saline) in a double-b…
Phase 2 • Sponsor: Red de Terapia Celular • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Can an ancient herbal remedy tame rheumatoid arthritis?
Disease control Recruiting nowThis study tests whether adding a Chinese herbal formula (Si Miao Xiao Bi Tang) to standard rheumatoid arthritis medication can improve symptoms. About 132 adults with active RA will receive either the herbal medicine or a placebo for 12 weeks. The main goal is to see if more peo…
Phase 2/3 • Sponsor: Singapore General Hospital • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can trained immune cells stop blood cancer relapse?
Disease control Recruiting nowThis trial tests whether giving patients special immune cells, called TAA-T, after a stem cell transplant can help prevent high-risk blood cancers like acute myeloid leukemia from coming back. The cells are designed to recognize three common tumor markers and attack any remaining…
Phase 1 • Sponsor: Catherine Bollard • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Could a gut microbiome transplant ease axial spondyloarthritis?
Disease control Recruiting nowThis trial tests whether transferring gut bacteria from a healthy donor (fecal microbiota transplantation, or FMT) can reduce disease activity in people with axial spondyloarthritis (axSpA) who haven't fully responded to biologic therapy. Participants receive a single enema with …
Phase 2 • Sponsor: University Hospital of North Norway • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can Ultrasound-Guided shock waves dissolve shoulder calcium deposits?
Disease control Recruiting nowThis trial investigates whether using real-time ultrasound to guide shock wave therapy improves outcomes for people with calcific tendinitis of the shoulder, a painful condition where calcium deposits form in the rotator cuff tendons. Participants aged 20 to 70 with confirmed dep…
Sponsor: Taipei Medical University WanFang Hospital • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a Three-Drug combo quiet lupus kidney flares?
Disease control Recruiting nowThis trial tests whether adding voclosporin to standard lupus nephritis treatment (mycophenolate mofetil and prednisolone) reduces kidney inflammation faster and more completely than standard treatment alone. Adults with active lupus nephritis will be randomly assigned to either …
Phase 4 • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a Tumor-Injected drug combo outlast standard care in advanced sarcoma?
Disease control Recruiting nowThis phase 3 trial is testing whether an investigational drug called INT230-6, which combines three anti-cancer agents and is injected directly into tumors, can help people with advanced soft tissue sarcoma live longer than those receiving standard care. The study enrolls adults …
Phase 3 • Sponsor: Intensity Therapeutics, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could a once-every-few-weeks IV infusion tame rheumatoid arthritis?
Disease control Recruiting nowThis study tests whether giving sarilumab (Kevzara) through an IV with longer intervals between doses is safe and works well for adults with moderate-to-severe rheumatoid arthritis. Participants receive the drug intravenously, with or without other standard arthritis medications.…
Phase 1/2 • Sponsor: Sanofi • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a tailored chemo cocktail outsmart a common leukemia?
Disease control Recruiting nowThis trial is testing whether a chemotherapy combination called HAD, given at intermediate doses, works better than the standard regimen for people with a specific genetic subtype of acute myeloid leukemia (AML) known as CEBPA double-mutated. The study enrolls adults aged 14 to 5…
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for kids with arthritis: Long-Term drug study launches
Disease control Recruiting nowThis study is testing the long-term safety and effectiveness of the drug filgotinib in children and adolescents aged 8 to 17 with juvenile idiopathic arthritis. Participants must have already completed a previous filgotinib study and shown improvement. The goal is to see if the d…
Phase 3 • Sponsor: Alfasigma S.p.A. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can less be more? trial tests cutting RA medication doses
Disease control Recruiting nowThis trial asks whether people with rheumatoid arthritis who have low disease activity can safely reduce their JAK inhibitor dose without losing control of their symptoms. Participants will either follow a step-by-step dose-tapering plan or continue their usual full-dose medicati…
Phase 4 • Sponsor: University Hospital, Toulouse • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Personalized maintenance therapy: a smarter way to treat advanced cancer?
Disease control Recruiting nowThis phase II trial is testing whether continuing targeted therapy or immunotherapy based on a tumor's molecular profile can benefit patients with advanced solid tumors that have stopped responding to prior treatment. After an initial treatment period, patients whose disease is s…
Phase 2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a gentler steroid dose protect children's kidneys without the harsh side effects?
Disease control Recruiting nowThis trial compares two starting doses of the steroid prednisone for children with lupus-related kidney inflammation (lupus nephritis). The standard high dose can cause serious side effects like growth problems and bone thinning. The study asks whether a lower initial dose can co…
Phase 4 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Massive AML trial aims to find best chemo and transplant protection for younger patients
Disease control Recruiting nowThis study tests different chemotherapy doses and a drug to prevent graft-versus-host disease in adults aged 18 to 60 with newly diagnosed acute myeloid leukemia. Participants receive either idarubicin or daunorubicin during initial chemo, followed by high or intermediate doses o…
Phase 2/3 • Sponsor: University Hospital, Angers • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Which RA drug works best after the first one fails? a major trial aims to find out
Disease control Recruiting nowThis study compares two treatment strategies for people with active rheumatoid arthritis (RA) who have already tried a type of biologic called a TNF inhibitor. Participants are randomly assigned to switch to either a different class of biologic (non-TNFi) or a newer oral medicati…
Phase 3 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New combo therapy aims to tame heart sarcoidosis with fewer side effects
Disease control Recruiting nowThis Phase 3 trial compares a low-dose combination of prednisone and methotrexate to standard high-dose prednisone for people with active cardiac sarcoidosis. Researchers hope the combo works just as well but causes fewer side effects and improves quality of life. The study plans…
Phase 3 • Sponsor: Ottawa Heart Institute Research Corporation • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Shoulder surgery showdown: which biceps fix works best?
Disease control Recruiting nowThis trial compares two surgical methods for treating long head of the biceps tendon or SLAP lesions in people without full-thickness rotator cuff tears. One technique uses a self-locking mechanism, the other a 360 suture anchor. The goal is to see which provides better shoulder …
Sponsor: Clinique Générale dAnnecy • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Double-Barreled attack: Gene-Edited stem cells and CAR T-Cells take on tough leukemia
Disease control Recruiting nowThis trial tests a two-part treatment for people with acute myeloid leukemia (AML) that has not responded to standard therapy. First, patients receive a stem cell transplant from a healthy donor, but the stem cells are gene-edited to hide from the second treatment: specially engi…
Phase 1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Could a diabetes drug help leukemia patients stay off cancer pills?
Disease control Recruiting nowThis study tests whether adding pioglitazone (a diabetes drug) to standard tyrosine kinase inhibitors (TKIs) can help people with chronic myeloid leukemia (CML) who lost remission after stopping TKI therapy. Participants take the combination for at least six months, then stop all…
Phase 2 • Sponsor: Versailles Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New radiation approach aims to spare healthy tissue in sinus cancer treatment
Disease control Recruiting nowThis Phase 2 trial tests a new way to give radiation for sinus cancer after endoscopic surgery. Instead of radiating the whole sinus area, doctors will use a 'dose painting' technique that targets only the areas where cancer was found. The goal is to see if this reduces side effe…
Phase 2 • Sponsor: Centre Francois Baclesse • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Second-Time ACL repair: new technique shows promise for knee stability
Disease control Recruiting nowThis study looks at how well a particular revision ACL surgery works over the long term. The technique uses a donor Achilles tendon and an extra stitch on the outside of the knee. Researchers will check knee function, stability, and arthritis development in 59 people who had this…
Sponsor: Stefano Zaffagnini • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Blood test could help rheumatoid arthritis patients safely reduce medication
Disease control Recruiting nowThis study tests a new tool called OPTIBIO that uses blood markers and patient data to help doctors decide if it's safe to reduce biological therapy in rheumatoid arthritis patients who are in remission. About 184 adults with RA in stable remission will be randomly assigned to ha…
Sponsor: Francisco J. Blanco • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Morning or evening? timing your RA pill could boost relief
Disease control Recruiting nowThis study tests whether taking a once-daily JAK inhibitor for rheumatoid arthritis in the evening works better than taking it in the morning. About 90 adults with RA who qualify for this medication will be randomly assigned to morning or evening dosing. Researchers will compare …
Sponsor: Centre Hospitalier Princesse Grace • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New combo aims to beat High-Risk leukemia and MDS
Disease control Recruiting nowThis phase II trial tests whether adding targeted total marrow irradiation to standard chemotherapy before a stem cell transplant can improve outcomes for people with high-risk acute myeloid leukemia, chronic myeloid leukemia, or myelodysplastic syndromes. The study will enroll 3…
Phase 2 • Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New combo therapy targets tough leukemia in older patients
Disease control Recruiting nowThis early-phase trial is testing whether adding the drug daratumumab to standard chemotherapy can help adults aged 60 and older with a high-risk form of acute myeloid leukemia (AML). The main goal is to find the safest dose of daratumumab when given alongside chemotherapy. The s…
Phase 1 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Engineered immune cells take on tough leukemia in early trial
Disease control Recruiting nowThis early-stage trial tests a new treatment called ICG415 CAR-T cells for adults with acute myeloid leukemia that has come back or not responded to standard therapy. The treatment involves taking a patient's own immune cells, engineering them to recognize and attack leukemia cel…
Phase 1 • Sponsor: iCell Gene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Can a Tight-Control strategy tame lupus?
Disease control Recruiting nowThis study tests whether a 'treat-to-target' approach—where doctors adjust treatment every 6 weeks to aim for remission—works better than usual care for people with lupus. About 606 participants who are not in remission will be followed for 120 weeks. The goal is to see if this s…
Sponsor: Heinrich-Heine University, Duesseldorf • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a simple injection tame stubborn achilles pain?
Disease control Recruiting nowThis trial investigates whether adding up to three corticosteroid injections to standard exercise therapy improves pain and function in adults with chronic midportion Achilles tendinopathy. Participants receive either the steroid injection or a placebo (lidocaine only), alongside…
Phase 3 • Sponsor: Erasmus Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Drug combo aims to halt lung scarring in scleroderma
Disease control Recruiting nowThis trial tests whether adding rituximab to standard mycophenolate mofetil (MMF) therapy can improve lung function in people with severe lung scarring caused by systemic sclerosis. About 102 adults with this condition will receive either rituximab infusions plus MMF or placebo i…
Phase 3 • Sponsor: University Hospital, Tours • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New pill could ease juvenile arthritis in kids
Disease control Recruiting nowThis study tests a daily pill called filgotinib in children aged 8 to 17 with a type of arthritis that affects multiple joints. The goal is to see if the drug is safe and helps control the disease over 18 weeks. About 65 participants will take the drug and be monitored for side e…
Phase 3 • Sponsor: Alfasigma S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Could a common drug improve stem cell transplants for a rare bone marrow cancer?
Disease control Recruiting nowThis early-phase study tests whether adding pegylated interferon alfa-2a after a stem cell transplant can help control myelofibrosis, a type of bone marrow cancer. About 18 adults with primary or secondary myelofibrosis will receive the drug after their transplant to find the saf…
Phase 1 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for rare muscle disease: baricitinib trial aims to cut steroid use
Disease control Recruiting nowThis Phase 3 trial tests whether baricitinib, a JAK inhibitor pill, can improve symptoms of dermatomyositis (a rare autoimmune disease causing muscle weakness and skin rashes) while allowing patients to stop steroids. 62 adults with active disease will receive baricitinib or a pl…
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for rare cancer: targeted drug afatinib tested in fanconi anemia patients
Disease control Recruiting nowThis study tests a drug called afatinib in 25 adults with Fanconi anemia who have advanced head and neck cancer that cannot be removed by surgery. Afatinib is a pill that blocks a protein helping cancer grow. The goal is to see if it can shrink tumors and control the disease. Res…
Phase 1/2 • Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Engineered immune cells take on relapsed blood cancers
Disease control Recruiting nowThis early-phase trial is testing a new type of CAR-T cell therapy, called CD19-CAR.p40-T, in 10 adults with B-cell lymphoma, acute lymphoblastic leukemia, or acute myeloid leukemia that has come back or not responded to treatment. Participants receive chemotherapy followed by an…
Phase 1/2 • Sponsor: Shenzhen University General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New trial aims to match AML patients with best drug combo
Disease control Recruiting nowThis phase 2 trial tests whether adding venetoclax to standard intensive chemotherapy improves outcomes for adults with acute myeloid leukemia (AML). The study will enroll 380 patients aged 14 to 60 to see which genetic subtypes benefit most. Researchers hope to personalize treat…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for rare tumor patients: chemo delivered directly to desmoid growths
Disease control Recruiting nowThis study is for people with symptomatic desmoid tumors that are growing and cannot be treated with surgery or freezing. Researchers are testing a procedure that delivers chemotherapy (doxorubicin) directly into the tumor through a small tube in an artery, aiming to shrink the t…
Sponsor: Istituto Ortopedico Rizzoli • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New trial aims to tame transplant complications in blood cancer patients
Disease control Recruiting nowThis phase II trial tests different drug combinations to prevent graft-versus-host disease (GVHD) in 400 blood cancer patients receiving stem cell transplants from unrelated donors. Participants will receive either thymoglobulin or a combination of cyclophosphamide with other imm…
Phase 2 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Heart shield for chemo: new trial aims to protect AML patients
Disease control Recruiting nowThis study tests whether giving two common heart medications (a beta blocker and an ACE inhibitor) before and during intensive chemotherapy can prevent heart damage in people newly diagnosed with acute myeloid leukemia (AML). About 70 adults will be randomly assigned to receive t…
Phase 2 • Sponsor: University of Virginia • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for kids with tough leukemia: drug combo enters human testing
Disease control Recruiting nowThis early-stage trial is testing whether adding the drug talazoparib to standard chemotherapy is safe for children and young adults up to age 21 whose acute myeloid leukemia (AML) has returned or not responded to treatment. About 34 participants will receive different doses to f…
Phase 1 • Sponsor: Norman J. Lacayo • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can AI learn to spot endometriosis and fibroids on ultrasound?
Diagnosis Recruiting nowResearchers at Semmelweis University are building and testing artificial intelligence algorithms that read standardized transvaginal ultrasound images. The study includes women aged 18 to 45 who have suspected endometriosis or adenomyosis, a confirmed uterine mass scheduled for s…
Sponsor: Semmelweis University • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
Can a weekly dipstick at home catch lupus kidney damage early?
Diagnosis Recruiting nowPeople with lupus can develop kidney inflammation called lupus nephritis, which is easier to treat when caught early. This study enrolls adults with lupus who are at higher risk for kidney problems and assigns them by chance to either standard care alone or standard care plus wee…
Sponsor: NYU Langone Health • Aim: Diagnosis
Last updated Sep 18, 2026 00:00 UTC
-
Can advanced imaging reveal hidden swallowing muscle damage in IBM?
Diagnosis Recruiting nowResearchers at Johns Hopkins University are studying whether neuromuscular ultrasound and MRI can serve as reliable markers of swallowing muscle problems in people with inclusion body myositis (IBM). The study compares imaging and clinical findings in 30 participants, including p…
Sponsor: Johns Hopkins University • Aim: Diagnosis
Last updated Sep 18, 2026 00:00 UTC
-
A new brain scan tracer aims to light up myelin damage
Diagnosis Recruiting nowResearchers at Yale University are testing a PET imaging tracer called [18F]3F4AP to see whether it can measure demyelination, the loss of the protective myelin sheath around nerve fibers. The study includes healthy volunteers and people with conditions such as multiple sclerosis…
Phase 1 • Sponsor: Yale University • Aim: Diagnosis
Last updated Sep 11, 2026 00:00 UTC
-
New screening tool aims to catch hidden arthritis in psoriasis patients
Diagnosis Recruiting nowThis Canadian study tests whether adding two questions about morning stiffness and lower back pain to a standard screening tool (PEST) can help dermatologists identify psoriatic arthritis earlier in people with moderate-to-severe plaque psoriasis. About 502 adults who are candida…
Sponsor: Novartis Pharmaceuticals • Aim: Diagnosis
Last updated Sep 11, 2026 00:00 UTC
-
Can a simple blood test catch Cushing's earlier?
Diagnosis Recruiting nowThis study aims to improve how doctors diagnose Cushing's syndrome, a condition caused by too much cortisol. Researchers will test the accuracy of the desmopressin stimulation test in 140 people aged 18-70 who have or may have Cushing's, plus healthy volunteers. Participants will…
Phase 2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Diagnosis
Last updated Sep 02, 2026 00:00 UTC
-
A glowing dye could expose hidden heart scarring
Diagnosis Recruiting nowThis study tests whether a new radioactive dye, 68Ga-FAPI, can spot active scarring in the heart muscle using PET-MR scans. Researchers will scan about 290 people with various heart muscle conditions, such as heart failure with preserved ejection fraction, hypertrophic cardiomyop…
Sponsor: University of Edinburgh • Aim: Diagnosis
Last updated Aug 28, 2026 00:00 UTC
-
New heel pain test could replace costly scans
Diagnosis Recruiting nowThis study tests two simple physical exam techniques to see if they can accurately diagnose chronic plantar fasciopathy, a common cause of heel pain. Researchers will compare these tests in 45 adults—some with the condition and some without—to measure how well they work. If prove…
Sponsor: Istituto Ortopedico Rizzoli • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
Ultrasound may replace costly CT scans for lung disease in arthritis patients
Diagnosis Recruiting nowThis study tests whether a quick, non-invasive lung ultrasound can detect interstitial lung disease in people with rheumatoid arthritis. About 280 adults with RA and risk factors for lung disease will get an ultrasound, and results will be compared to standard chest CT scans. If …
Sponsor: University Hospital, Tours • Aim: Diagnosis
Last updated Jun 27, 2026 12:26 UTC
-
Simple blood test could spare prostate cancer patients from unnecessary scans
Diagnosis Recruiting nowThis study aims to develop a blood test that detects RNA from tiny particles (exosomes) to predict if prostate cancer has spread to the bones. Researchers will analyze blood samples from 1,000 men with newly diagnosed prostate cancer and compare results with PSMA PET scans. The g…
Sponsor: Xijing Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:24 UTC
-
Sugar compound in dental wipes may shield kids with leukemia from deadly infections
Prevention Recruiting nowThis phase 3 trial tests whether xylitol dental wipes can reduce bloodstream infections in children with acute myeloid leukemia (AML). Xylitol, a natural sugar that limits mouth bacteria growth, is applied via wipes during chemotherapy. The study will compare infection rates betw…
Phase 3 • Sponsor: Children's Oncology Group • Aim: Prevention
Last updated Sep 06, 2026 00:00 UTC
-
Can a simple gel shield fertility after fibroid surgery?
Prevention Recruiting nowThis trial tests whether placing a special gel inside the uterus after fibroid removal surgery can prevent the formation of scar tissue (adhesions) that may harm fertility. Women aged 18 to 45 who are scheduled for laparoscopic or abdominal myomectomy and have no pre-existing ute…
Sponsor: University Hospital, Ghent • Aim: Prevention
Last updated Aug 22, 2026 00:00 UTC
-
Blood thinner may stop autoimmune disease before it starts
Prevention Recruiting nowThis trial tests whether clopidogrel, a common blood thinner, can prevent systemic sclerosis (scleroderma) in people who have Raynaud phenomenon and specific antibodies that put them at high risk. About 47% of such individuals develop full scleroderma within five years. Participa…
Phase 2/3 • Sponsor: University Hospital, Bordeaux • Aim: Prevention
Last updated Jul 09, 2026 00:00 UTC
-
Green tea and vitamin D3 may stop fibroids returning after surgery
Prevention Recruiting nowThis study tests whether taking green tea extract (EGCG) and vitamin D3 daily can prevent uterine fibroids from growing back after surgical removal. About 240 women who have had fibroid surgery will receive either the supplements or a placebo. The goal is to see if this simple co…
Phase 2 • Sponsor: Sheikh Shakhbout Medical City • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
Poop pills to prevent transplant rejection? new trial tests fecal transplants in blood cancer patients
Prevention Recruiting nowThis study tests whether a fecal microbiota transplant (FMT) can prevent graft-versus-host disease (GvHD) in 150 adults with blood cancers who receive a stem cell transplant. Patients get a single FMT enema within four weeks of transplant. The main goal is to see if FMT improves …
Phase 2 • Sponsor: University Hospital, Clermont-Ferrand • Aim: Prevention
Last updated Jun 27, 2026 13:04 UTC
-
Neck scan could predict heart attacks in arthritis patients
Prevention Recruiting nowThis study tests whether using a carotid ultrasound (a neck scan) to find hidden plaque in arteries can help prevent heart attacks and strokes in people with inflammatory rheumatic diseases like rheumatoid arthritis or lupus. About 1,944 participants aged 50 and older will be spl…
Phase 4 • Sponsor: Instituto de Investigación Marqués de Valdecilla • Aim: Prevention
Last updated Jun 27, 2026 12:39 UTC
-
Vitamin e gel could stop Dupuytren's before fingers curl
Prevention Recruiting nowThis study tests if a vitamin E treatment can shrink early-stage Dupuytren's nodules (painless lumps in the palm) and prevent them from turning into disabling finger contractures. About 80 adults with stage 0 Dupuytren's will receive either vitamin E or a placebo, and doctors wil…
Phase 2 • Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Prevention
Last updated Jun 27, 2026 12:32 UTC
-
Ear-Zapping device may quiet lupus pain and fatigue
Symptom relief Recruiting nowResearchers are testing whether a handheld device that stimulates the vagus nerve through the skin can reduce musculoskeletal pain and fatigue in people with systemic lupus erythematosus. Eighteen participants will use the device for five minutes daily for 28 days, with some rece…
Phase 2 • Sponsor: Northwell Health • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
New needle technique aims to ease back pain in ankylosing spondylitis
Symptom relief Recruiting nowThis study tests a new, ultrasound-guided acupotomy technique to improve symptoms in people with ankylosing spondylitis, a type of arthritis that causes back pain and stiffness. About 60 adults with active disease will receive the treatment to see if it reduces pain and improves …
Sponsor: China-Japan Friendship Hospital • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Shock waves for stiff heart valves: new balloon tested in First-in-Human trial
Symptom relief Recruiting nowResearchers are testing a new balloon device called SmartWave that uses shock waves to break up calcium in severely narrowed mitral valves. The study enrolls 10 adults with symptomatic mitral stenosis caused by mitral annular calcification or severely calcified rheumatic heart di…
Sponsor: Prince of Wales Hospital, Shatin, Hong Kong • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Lavender massage may soothe arthritis pain, new study says
Symptom relief Recruiting nowThis study tests whether adding lavender aromatherapy massage to standard care can reduce pain and improve wrist movement in people with rheumatoid arthritis. About 100 adults with stable medication will be randomly assigned to get the massage or not. Researchers will measure pai…
Sponsor: University of Baghdad • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
New gel injection aims to soothe sore tendons
Symptom relief Recruiting nowThis study is testing a gel called OSTENIL TENDON to see if it safely reduces pain and improves movement in people with tendon problems. Researchers will enroll 84 adults with one of four types of tendinopathy. The main goal is to measure pain changes three months after treatment…
Sponsor: TRB Chemedica AG • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
A new ankle? researchers track 400 people with an implant meant to restore movement
Symptom relief Recruiting nowResearchers are studying the Exactech Vantage Mobile-Bearing Total Ankle System, an implant used to replace a damaged ankle joint. The study enrolls 400 adults with ankle arthritis or related joint failure who are scheduled for total ankle replacement. Participants receive the im…
Sponsor: Exactech • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Can a new ankle implant keep people moving for a decade?
Symptom relief Recruiting nowResearchers are studying the Exactech Vantage Total Ankle System, an implant used to replace a damaged ankle joint in people with arthritis or a failed previous replacement. The study enrolls 370 adults who are candidates for total ankle replacement and follows them for up to 10 …
Sponsor: Exactech • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Can talk therapy and symptom tracking ease the trauma of leukemia?
Symptom relief Recruiting nowThis study tests a program called EASE that combines psychological support with regular symptom checks and early access to palliative care. Researchers want to see if it reduces traumatic stress and physical symptoms in people newly diagnosed with acute leukemia. Half of the 266 …
Sponsor: Canadian Cancer Trials Group • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
Could a citrus compound heal scleroderma finger ulcers?
Symptom relief Recruiting nowThis study tests whether diosmin, a citrus-based supplement, can safely heal open sores on the fingers of people with scleroderma. About 45 adults with at least one active digital ulcer will take either diosmin or a placebo for 8 weeks. Researchers will track ulcer healing, pain,…
Sponsor: Primus Pharmaceuticals • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Can fewer acupuncture sessions tame chronic heel pain?
Symptom relief Recruiting nowResearchers are comparing two schedules of electroacupuncture for adults with chronic plantar fasciitis, a common cause of heel pain. Participants receive either one session per week or three sessions per week for four weeks. The trial measures whether at least half of participan…
Sponsor: Guang'anmen Hospital of China Academy of Chinese Medical Sciences • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Lower back nerve block tested to cut pain after fibroid surgery
Symptom relief Recruiting nowResearchers are testing whether a quadratus lumborum nerve block reduces pain after laparoscopic myomectomy, a surgery to remove uterine fibroids while keeping the uterus. The block is a temporary anesthetic injection into a lower back muscle. In this double-blind, randomized tri…
Phase 4 • Sponsor: Joseph Findley MD • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Pre-transplant workout may shield heart in older leukemia patients
Symptom relief Recruiting nowThis study tests a home-based exercise program called CAREFit-BMT for people with high-risk acute myeloid leukemia who are about to have a stem cell transplant. The program includes aerobic and strength training to improve heart function before the procedure. Researchers will enr…
Sponsor: University of Washington • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Can collagen shots around the heel tendon speed recovery?
Symptom relief Recruiting nowAchilles tendinopathy is a painful condition of the tendon at the back of the ankle. Researchers are testing whether injecting a collagen-based medical device around the tendon, combined with a physiotherapy program of eccentric strengthening exercises, improves pain and function…
Sponsor: Guna S.p.a • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Fish or puppets: which distraction works best for needle-phobic kids?
Symptom relief Recruiting nowThis trial tests whether two simple distractions — watching a betta fish or playing with a hand puppet — can lower pain, fear, and anxiety in children aged 5 to 7 during a blood draw. One group will use the fish, another the puppet, and a third will receive standard care. Researc…
Phase 1 • Sponsor: Igdir University • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Can a smart platform ease the toll of childhood cancer on families?
Symptom relief Recruiting nowThis trial tests two digital platforms, one for children with cancer and one for their parents, designed to improve communication with healthcare providers and address physical, emotional, social, and spiritual needs during treatment. Researchers will recruit 120 families of chil…
Sponsor: National Defense Medical University, Taiwan • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
Which injection eases arm pain better: steroid or Anti-Inflammatory?
Symptom relief Recruiting nowThis trial tests two common injections for pain in the shoulder, elbow, wrist, or hand caused by arthritis or tendon problems. One injection is triamcinolone, a corticosteroid that reduces inflammation. The other is ketorolac, a non-steroidal anti-inflammatory drug (NSAID). Parti…
Phase 4 • Sponsor: Emory University • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
Could a gentle nerve zap ease jaw pain? new study tests it
Symptom relief Recruiting nowThis pilot study will test whether a non-invasive vagus nerve stimulation (nVNS) device can reduce jaw pain and improve mood in 10 premenopausal women with temporomandibular disorders (TMD). Participants will receive the treatment twice a week for 8 weeks and undergo brain scans,…
Sponsor: Arpana Church • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Can tailored exercise help young sarcoma survivors recover strength?
Symptom relief Recruiting nowThis study tests whether a personalized exercise program can improve physical function and quality of life in adolescents and young adults who have survived sarcoma. Participants first complete a triage tool to assess their needs, then receive a 12-week exercise plan that may inc…
Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Aug 28, 2026 00:00 UTC
-
Could a walk a day keep brain fog away after a stem cell transplant?
Symptom relief Recruiting nowThis study tests whether a tailored physical activity program can help older adults maintain thinking and memory after a stem cell transplant for blood cancers. Participants aged 60 and older will follow a progressive, light-to-moderate exercise plan with support from therapists …
Sponsor: University of Nebraska • Aim: Symptom relief
Last updated Aug 21, 2026 00:00 UTC
-
Talking about the end: could guided conversations reduce futile cancer treatments?
Symptom relief Recruiting nowThis trial tests a program called ACT, which trains doctors and nurses to have compassionate, structured conversations with blood cancer patients and their families about end-of-life care. The goal is to help patients understand their prognosis and make informed decisions, potent…
Sponsor: Christoffer Johansen • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
A simple diet and muscle relaxant may sharpen views in scarless hysterectomy
Symptom relief Recruiting nowThis trial tests whether a three-day low-residue diet and deeper muscle relaxation, alone or together, can improve the surgical view during vNOTES hysterectomy (a scarless procedure through the vagina). The study involves 160 women having hysterectomy for non-cancer conditions. R…
Sponsor: Fatih Sultan Mehmet Training and Research Hospital • Aim: Symptom relief
Last updated Aug 01, 2026 00:00 UTC
-
Could a Two-Drug shot beat the standard for shoulder pain?
Symptom relief Recruiting nowThis study tests whether adding hyaluronic acid to a standard corticosteroid injection works better for shoulder tendonitis pain than the steroid alone. About 132 adults with confirmed supraspinatus tendinopathy will receive either the combo or a placebo injection. Pain levels ar…
Phase 3 • Sponsor: Centre Hospitalier Departemental Vendee • Aim: Symptom relief
Last updated Jul 12, 2026 00:00 UTC
-
Heel pain relief during pregnancy: which Hands-On therapy works best?
Symptom relief Recruiting nowThis study compares two manual therapy techniques—myofascial release and instrument-assisted soft tissue mobilization—for treating plantar fasciitis in pregnant women. Forty-four women in their second or third trimester will receive one of the two treatments over four weeks, alon…
Sponsor: University of Lahore • Aim: Symptom relief
Last updated Jul 10, 2026 00:00 UTC
-
Can facial exercises ease the stiffness of scleroderma?
Symptom relief Recruiting nowThis study tests whether a personalized facial rehabilitation program can help people with systemic sclerosis who have facial tightness and mouth problems. About 60 adults with this rare autoimmune disease will either receive the rehab program or standard care. The goal is to see…
Sponsor: University Hospital, Strasbourg, France • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
New study aims to ease chronic pain without pills for military personnel
Symptom relief Recruiting nowThis study is testing two holistic, non-drug programs to help military members manage chronic musculoskeletal pain. About 608 participants will be randomly assigned to either a single-session class called Empowered Relief, a multi-session program called Move to Health, or usual c…
Sponsor: Brooke Army Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Could a single palliative care visit improve life for bone metastasis patients?
Symptom relief Recruiting nowThis study tests whether offering a palliative care consultation early—when patients with advanced cancer and bone metastases start radiotherapy—improves their satisfaction with care and quality of life. About 246 participants will be randomly assigned to receive either a tailore…
Phase 2 • Sponsor: Roxanne Gal • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Blocking blood flow to bone tumors may offer pain relief without major surgery
Symptom relief Recruiting nowThis study looks at whether a procedure called arterial embolization can reduce pain and improve quality of life in people with bone metastases (cancer that has spread to the bones). The procedure blocks blood flow to the tumor, which may shrink it and ease symptoms. Researchers …
Sponsor: Istituto Ortopedico Rizzoli • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Magic mushroom therapy tested for depression in chronic illness patients
Symptom relief Recruiting nowThis study tests whether psilocybin (the active ingredient in magic mushrooms) can safely reduce depression in adults with COPD, ALS, MS, or atypical Parkinson disease who have at least 6 months to live. Participants receive either two moderate-to-high doses (15mg then 25mg) or t…
Phase 2 • Sponsor: University Medical Center Groningen • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
New study tests online fatigue programs for lupus patients
Symptom relief Recruiting nowThis study tests whether online group programs to manage fatigue can help people with lupus. Participants will either receive a fatigue booklet alone or also attend online group sessions (4 or 7 weeks long). The goal is to see if the programs reduce fatigue impact and improve qua…
Sponsor: University of Edinburgh • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Thinking away heel pain: new study tests brain training for plantar fasciitis
Symptom relief Recruiting nowThis study tests whether cognitive training (brain exercises) can reduce pain and improve balance in people with plantar fasciitis, a common cause of heel pain. Eighty adults will be split into two groups: one doing cognitive training plus stretching, the other doing only stretch…
Sponsor: Beni-Suef University • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Gene hunt in peru: could ancestry hold key to autoimmune diseases?
Knowledge-focused Recruiting nowThis study aims to uncover genetic changes that cause autoimmune diseases in people native to Peru. Researchers will collect blood, urine, and stool samples from 300 participants, including patients with conditions like lupus and rheumatoid arthritis, their family members, and he…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Lupus drug anifrolumab under pregnancy safety spotlight
Knowledge-focused Recruiting nowThis study is tracking 500 pregnant women with lupus to see if the drug anifrolumab is linked to birth defects or pregnancy loss. Researchers will compare women who took anifrolumab during early pregnancy to those who did not. The goal is to gather real-world safety data, not to …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New screening trial aims to speed up matching of cancer patients to the right treatments
Knowledge-focused Recruiting nowThis study tests a new way to screen patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) by analyzing their bone marrow and blood for specific biomarkers. The goal is to quickly match patients with a treatment trial that targets their cancer's unique mark…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New study checks drug levels in breast milk for nursing moms
Knowledge-focused Recruiting nowThis study looks at how much of the drug bimekizumab passes into breast milk. Researchers will collect milk samples from 20 breastfeeding mothers with conditions like psoriasis or arthritis over several weeks. The goal is to understand potential exposure for nursing infants, not …
Phase 1 • Sponsor: UCB Biopharma SRL • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Coin flip chemo: study tests if patients will let a computer choose their treatment strength
Knowledge-focused Recruiting nowThis study looks at whether adults with acute myeloid leukemia (AML) who are not healthy enough for strong chemotherapy are willing to let a computer randomly assign them to either lower- or higher-intensity treatment. The goal is to see if this approach is acceptable to patients…
Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Massive shoulder replacement study tracks 20,000 patients for over a decade
Knowledge-focused Recruiting nowThis study is tracking 20,000 people who have had or will have shoulder replacement surgery to see how well the implants work over at least 10 years. Researchers will measure pain, daily function, and strength using standard shoulder scores. The goal is to better understand the l…
Sponsor: Exactech • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Massive study aims to unlock secrets of rare inflammatory diseases
Knowledge-focused Recruiting nowThis study is for people with certain autoinflammatory diseases (like NOMID, DIRA, CANDLE, SAVI, and others) and their healthy relatives. Researchers want to learn more about what causes these diseases and how they affect the body over time. Participants will have medical tests a…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists watch thyroid conditions unfold in 2,500 patients
Knowledge-focused Recruiting nowThis study follows up to 2,500 people with thyroid problems like hyperthyroidism, hypothyroidism, or Graves' disease. Researchers will track how these conditions develop over time using standard medical tests and genetic samples. The goal is to better understand the natural histo…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Lupus secrets revealed: major study tracks disease over time
Knowledge-focused Recruiting nowThis study aims to learn more about how lupus (SLE) develops and changes over time by observing patients and their relatives. Up to 2000 people aged 3 and older with known or suspected lupus, along with their family members, will provide medical history, blood and urine samples, …
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
20,000 volunteers needed to decode immune disease genetics
Knowledge-focused Recruiting nowThis study will analyze DNA from up to 20,000 people, including those with immune disorders and their relatives, to find genetic variants linked to conditions like atopy, autoimmunity, and primary immunodeficiency. Researchers will also study how best to return genetic results to…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Rare bone disease under the microscope: what causes melorheostosis?
Knowledge-focused Recruiting nowThis study follows adults with melorheostosis, a rare disease that causes bone thickening, pain, and joint problems. Researchers will track how the disease progresses over time, collect genetic samples from patients and their relatives, and look for biomarkers. The goal is to bet…
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Can your genes predict eye damage from a common arthritis drug?
Knowledge-focused Recruiting nowThis study looks at whether certain genes make some people more likely to develop eye damage from the drug Plaquenil, which is used for autoimmune diseases like lupus and rheumatoid arthritis. Researchers will compare people who have had eye damage from Plaquenil with those who h…
Sponsor: National Eye Institute (NEI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Lupus drug anifrolumab under safety microscope: does it raise infection or cancer risk?
Knowledge-focused Recruiting nowThis study watches over 3,000 adults with moderate-to-severe lupus to see if the drug anifrolumab increases the risk of serious infections or cancer compared to standard treatments. No new medicine is given—researchers simply analyze health records from people already prescribed …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Massive study aims to unlock secrets of food allergies
Knowledge-focused Recruiting nowThis study looks at the causes and effects of food allergies and related conditions like eczema and eosinophilic esophagitis. Researchers will collect blood, skin, and genetic samples from up to 1,800 people over many years. The goal is to find biomarkers and pathways that explai…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Researchers launch major study to unravel mysteries of muscle disease
Knowledge-focused Recruiting nowThis study aims to learn more about myositis, a group of diseases that cause muscle inflammation and damage. Researchers will observe up to 1,200 children and adults with myositis, along with healthy volunteers, to track changes in the immune system and other health problems over…
Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Cured of cushing as a kid? scientists want to track your health for years
Knowledge-focused Recruiting nowThis study looks at the long-term health of people who were cured of Cushing disease before age 21. Researchers want to understand how past high cortisol levels affect the body and mind years later. Participants will complete surveys and have check-ups every 5 years. The goal is …
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Lupus drug in breast milk: new study aims to find out
Knowledge-focused Recruiting nowThis study tracks 16 breastfeeding mothers with lupus who are taking anifrolumab. Researchers will measure how much of the drug appears in breast milk and in the mother's and baby's blood. The goal is to understand potential exposure and effects on the breastfed infant.
Phase 4 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Joint tissue study aims to personalize rare disease treatment
Knowledge-focused Recruiting nowThis study looks at whether analyzing synovial tissue can help doctors better manage pigmented villonodular synovitis (PVNS), a rare joint disease that causes pain and joint damage. Researchers will collect tissue samples from 30 patients through biopsy or surgery to assess quali…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Scientists track spondyloarthritis in families to uncover clues to severe disease
Knowledge-focused Recruiting nowThis study follows up to 2,000 people with spondyloarthritis (a group of inflammatory joint and spine conditions) and their healthy relatives. Researchers aim to identify symptoms, genetic factors, and medical tests that predict who will develop more severe forms of the disease. …
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Real-World data may unlock Pacritinib's true potential in myelofibrosis
Knowledge-focused Recruiting nowThis study looks back at medical records of adults with myelofibrosis who took pacritinib for at least a month. Researchers will track changes in spleen size, blood counts, symptoms, and survival to see how the drug performs in everyday practice. The goal is to understand real-wo…
Sponsor: Swedish Orphan Biovitrum • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Scleroderma's hidden link: could pelvic floor trouble track with weaker lungs?
Knowledge-focused Recruiting nowScleroderma often scars the lungs, which can weaken breathing muscles and make exercise harder. Researchers want to know whether pelvic floor problems, such as incontinence or pelvic pain, go hand in hand with these lung and breathing changes. The study enrolls 67 women with scle…
Sponsor: Biruni University • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Can a smartwatch track how kids recover from cancer surgery?
Knowledge-focused Recruiting nowThis study is testing whether smartwatches and blood tests can measure how well children recover after surgery to remove a solid tumor. About 40 children and their caregivers will wear smartwatches and answer questionnaires before surgery and for up to a year after. Researchers w…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Massive Real-World database aims to map how chronic diseases interact
Knowledge-focused Recruiting nowOPERA is a large observational database that collects health records from people treated for chronic conditions such as HIV, liver disease, inflammatory bowel disease, heart disease, rheumatic disease, and neurodegenerative disease. Researchers use the records to study how these …
Sponsor: Epividian • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Telehealth program aims to improve end-of-life conversations for older cancer patients
Knowledge-focused Recruiting nowThis study tests a telehealth program that helps older adults (60+) with blood cancers like leukemia or MDS talk to their doctors about their care wishes. The program also helps them fill out advance directive forms. Researchers want to see if it improves communication and reduce…
Sponsor: University of Rochester • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Hidden cost of cancer: study probes financial toxicity in sarcoma patients
Knowledge-focused Recruiting nowThis study looks at the financial stress that patients with bone or soft tissue sarcoma face after surgery. Researchers will ask 100 adults to fill out questionnaires about the costs of their cancer care and how that affects their quality of life. No new treatments are being test…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Scientists track rare gene variant to unlock blood disorder mysteries
Knowledge-focused Recruiting nowThis study follows people of all ages who have or may have a RUNX1 gene variant, which can cause bleeding problems and increase the risk of blood cancers. Researchers will collect medical history, blood samples, and bone marrow over many years to understand how the condition deve…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Laser imaging may uncover secret triggers of lung disease
Knowledge-focused Recruiting nowThis study explores whether a technique called LIBS, which maps chemical elements in lung tissue, can help doctors identify possible environmental or workplace causes of chronic lung diseases. Researchers will analyze stored biopsy samples from 70 adult patients using LIBS and an…
Sponsor: University Hospital, Grenoble • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Lupus drug anifrolumab under scrutiny for pregnancy risks
Knowledge-focused Recruiting nowThis study tracks 240 pregnant women with lupus who have taken anifrolumab (Saphnelo) to see if the drug affects pregnancy or baby health. Researchers will monitor for birth defects and other complications. The goal is to gather safety information, not to test a new treatment.
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Disposable scope takes on gold standard in pleural diagnosis
Knowledge-focused Recruiting nowThis pilot trial tests whether a single-use flexible bronchoscope can safely and effectively replace the semi-rigid pleuroscope for diagnosing pleural effusion—a buildup of fluid around the lungs. Hospitalized patients needing a tissue sample will be randomly assigned to one of t…
Sponsor: National University of Malaysia • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Blood cancer registry tracks thousands to map disease course
Knowledge-focused Recruiting nowResearchers are building a registry to collect long-term health information from adults with myelodysplastic syndromes and therapy-related acute myeloid leukemia. The study gathers details on blood counts, bone marrow tests, genetic changes, and treatments. By following these pat…
Sponsor: Groupe Francophone des Myelodysplasies • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Scientists hunt for lung disease genes in 3,500 volunteers
Knowledge-focused Recruiting nowThis study looks at how genes play a role in lung diseases like cystic fibrosis, asthma, and pulmonary fibrosis. Researchers will examine DNA from up to 3,500 people with and without lung disease to find genetic differences. The goal is to better understand what causes these cond…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Scientists launch global effort to unravel mysteries of rare lymphatic diseases
Knowledge-focused Recruiting nowThis study is creating a registry of up to 1,000 people with rare lymphatic system disorders. Researchers will collect information from medical records and yearly surveys to understand how these diseases progress, what treatments are used, and how they affect quality of life. The…
Sponsor: Boston Children's Hospital • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
500-Patient study aims to unravel mysteries of rare immune diseases
Knowledge-focused Recruiting nowThis study follows 500 children and adults with rare genetic disorders called type I interferonopathies, which cause severe inflammation and neurological problems. Researchers will track how the disease progresses over time and look for biological markers to improve diagnosis and…
Sponsor: Imagine Institute • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Researchers launch study to unravel mysteries of rare immune disorder sHLH
Knowledge-focused Recruiting nowThis study aims to understand why some adults develop secondary hemophagocytic lymphohistiocytosis (sHLH), a serious immune condition causing fevers and organ damage. Researchers will follow 300 participants for up to 3 years, collecting blood samples and medical data to identify…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Scientists seek genetic clues to mysterious fever diseases
Knowledge-focused Recruiting nowThis study aims to learn more about the genetics and natural history of autoinflammatory diseases, which cause repeated fevers and inflammation. Researchers will study up to 5,000 people, including patients, their relatives, and healthy volunteers. Participants provide blood and …
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Blood protein clues may predict chemo success in older cancer patients
Knowledge-focused Recruiting nowThis study looks at 60 adults with acute myeloid leukemia or related blood cancers who are receiving a gentler type of chemotherapy. Researchers will measure certain proteins in the blood to see if they can predict how well the treatment works. The goal is to better understand wh…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Scientists hunt for genetic clues behind childhood pituitary tumors
Knowledge-focused Recruiting nowThis study aims to uncover the genetic causes of pituitary and hypothalamic tumors in children. Researchers will collect blood and tumor samples from up to 2,000 participants to analyze DNA and look for inherited patterns. The study also trains doctors and tests new MRI technique…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
A nationwide effort to map a rare blood Cancer's toll
Knowledge-focused Recruiting nowResearchers in Italy are building a large registry of adults newly diagnosed with myelodysplastic syndromes, a group of blood cancers where the bone marrow does not make enough healthy blood cells. The study will collect data on up to 10,000 people to measure how many new cases o…
Sponsor: Fondazione Italiana Sindromi Mielodisplastiche-ETS • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
Lupus patients who failed multiple drugs under observation in new study
Knowledge-focused Recruiting nowThis study is observing 223 people with active lupus (including kidney inflammation) who haven't gotten better with steroids and at least two immunosuppressants. Researchers want to see how well today's standard treatments work for these tough cases. The goal is to measure how ma…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Scientists hunt for clues in blood cancer samples to improve future treatments
Knowledge-focused Recruiting nowThis study is collecting blood, bone marrow, and leftover tissue samples from 550 people with acute myeloid leukemia or follicular lymphoma. Researchers will analyze the samples to find genetic markers that may predict how well treatments work or why some stop working. The goal i…
Sponsor: Tempus AI • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Could the mouth reveal clues about juvenile arthritis activity?
Knowledge-focused Recruiting nowThis observational study looks at whether oral health and the bacteria in saliva are linked to disease activity in children with juvenile idiopathic arthritis (JIA). Researchers will compare children with active disease to those in remission, examining their teeth, gums, oral hyg…
Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
2000 volunteers help create a gold standard for cancer blood tests
Knowledge-focused Recruiting nowThis study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…
Sponsor: Alliance for Clinical Trials in Oncology • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Lupus drug anifrolumab under scrutiny in pregnancy safety study
Knowledge-focused Recruiting nowThis study follows 442 pregnant women with moderate-to-severe lupus to see if taking the drug anifrolumab (Saphnelo) during pregnancy affects the health of mothers or their babies. Researchers will compare women who took the drug during pregnancy to those who did not, tracking bi…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Scientists launch major study to unravel mysteries of rare immune diseases
Knowledge-focused Recruiting nowThis study aims to understand the causes and progression of Common Variable Immunodeficiency (CVID) and related inborn errors of immunity. Researchers will observe up to 500 patients over time using blood tests, imaging, and other exams. The goal is to find better ways to diagnos…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
NIH launches study to unlock secrets of rare 'Black Urine' disease
Knowledge-focused Recruiting nowThis study aims to learn more about alkaptonuria, a rare genetic disease that causes a pigment to build up in bones and tissues, leading to arthritis and other problems. Researchers will evaluate 300 patients over several years using advanced medical tests. The goal is to better …
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
New imaging registry aims to sharpen cancer treatment precision
Knowledge-focused Recruiting nowThis study will collect data from 2,000 patients in the Netherlands and France who are receiving standard, minimally invasive cancer treatments like tumor ablation or catheter-based therapies for liver, lung, kidney, or bone cancers. During these procedures, a special CT scanner …
Sponsor: Mark C Burgmans, MD PhD • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
NIH launches major study to uncover why rheumatic diseases hit minorities harder
Knowledge-focused Recruiting nowThis study aims to learn more about the causes of rheumatic diseases—conditions that cause joint pain, stiffness, and swelling—and why they often affect minority groups more severely. Researchers will observe up to 7,500 adults with known or suspected rheumatic disease, providing…
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Tiny coil placed inside nose could help surgeons spot hidden brain tumors
Knowledge-focused Recruiting nowThis study tests a small MRI coil placed inside the sphenoid sinus during pituitary tumor surgery. The goal is to see if it can provide clearer images of tiny tumors that standard MRI often misses. About 70 adults with pituitary tumors will take part. The coil is inserted through…
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Scientists launch deep dive into mysterious inflammatory diseases
Knowledge-focused Recruiting nowThis study aims to understand the causes and progression of systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease (AOSD) by observing up to 2,000 participants over time. Researchers will collect medical history, blood samples, and genetic data to identify …
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Scientists dig into immune signals to unlock psoriasis mystery
Knowledge-focused Recruiting nowThis study looks at 40 adults with psoriasis—some with joint pain (psoriatic arthritis) and some without—to compare immune signals in their blood and skin. Researchers want to understand why some people develop joint problems. Participants give blood and skin samples for lab anal…
Sponsor: Poitiers University Hospital • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Could a single injection tame the immune system in lupus?
Knowledge-focused Recruiting nowThis early-stage trial is testing a single injection of an experimental drug called SHR-7012 in healthy adults. The main goal is to check how safe and tolerable the drug is, and how the body absorbs and processes it. The study involves about 50 participants aged 18 to 55, who wil…
Phase 1 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Can a national biobank network end the diagnostic odyssey for rare diseases?
Knowledge-focused Recruiting nowThis study aims to create a network of biobanks across Italy that collect and store biological samples and health data from people with rare diseases and their families. The goal is to standardize how samples are collected and shared, so researchers can access high-quality materi…
Sponsor: IRCCS Policlinico S. Donato • Aim: Knowledge-focused
Last updated Aug 29, 2026 00:00 UTC
-
Can daily habits shield RA hearts from artery stiffness?
Knowledge-focused Recruiting nowThis observational study looks at how physical activity, sedentary time, and sleep relate to early signs of heart and blood vessel disease in adults with rheumatoid arthritis. Participants will wear activity monitors for a week, answer health questionnaires, and undergo heart and…
Sponsor: São Paulo State University • Aim: Knowledge-focused
Last updated Aug 22, 2026 00:00 UTC
-
Could gum bacteria fuel scleroderma? a new study digs in
Knowledge-focused Recruiting nowThis study investigates whether systemic sclerosis, a rare autoimmune disease, changes the community of bacteria living in the mouth. Researchers will collect dental plaque samples from 30 participants—some with scleroderma and some without—to compare the types and functions of o…
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC
-
Can glucocorticoid treatment skew bone health tests? a study investigates
Knowledge-focused Recruiting nowThis study follows 160 people with inflammatory joint disease who are starting treatment with or without glucocorticoids, or receiving a glucocorticoid injection. Researchers will measure bone turnover markers (P1NP and CTX1) in blood samples every 4 weeks and up to 6 months afte…
Sponsor: Diakonhjemmet Hospital • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC
-
AI decodes the mystery of persistent pain in rheumatoid arthritis
Knowledge-focused Recruiting nowThis observational study aims to understand why some people with rheumatoid arthritis (RA) continue to experience chronic pain even when their inflammation is well-controlled. Researchers will compare two groups of RA patients—those with active disease and those in remission with…
Sponsor: 4th Military Clinical Hospital with Polyclinic, Poland • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
Could a simple blood test replace heart scans for sarcoidosis?
Knowledge-focused Recruiting nowThis study will collect blood samples from 115 adults with cardiac sarcoidosis to look for tiny particles called exosomes that might show whether the disease is active or quiet. The goal is to develop a simple blood test that could help doctors monitor the condition without needi…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Can skin biopsies unlock new treatments for scleroderma?
Knowledge-focused Recruiting nowThis study aims to understand the cellular and molecular mechanisms behind systemic sclerosis (SSc), a rare autoimmune disease that causes skin and organ fibrosis. Researchers will collect skin punch biopsies and blood samples from 500 participants, including those with SSc and h…
Sponsor: Relation Therapeutics • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Simple blood test could predict transplant complications
Knowledge-focused Recruiting nowThis study looks at a new method to measure special immune cells called iNKT cells in the blood of patients who have had a stem cell transplant. These cells may help predict serious complications like graft-versus-host disease (GvHD) and relapse. Researchers will test 75 adults w…
Sponsor: University Hospital Pilsen • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Could a simple blood test flag heart risk in rheumatoid arthritis?
Knowledge-focused Recruiting nowThis study looks at whether certain markers of oxidative stress in the blood are linked to early signs of heart disease in people with rheumatoid arthritis. Researchers will measure these markers and check for thickening or stiffness in the carotid arteries. The goal is to better…
Sponsor: University of La Laguna • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
A simple blood test may reveal hidden infertility risk in young cancer survivors
Knowledge-focused Recruiting nowThis study investigates whether a blood marker called anti-Müllerian hormone (AMH) can predict future infertility in children and adolescents who have undergone cancer treatment. Many young patients recover normal menstrual cycles or puberty after chemotherapy, but their ovarian …
Sponsor: Erasme University Hospital • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
AI platform aims to unlock Real-World cancer data on a massive scale
Knowledge-focused Recruiting nowThis study enrolls people diagnosed with cancer to build a large registry using Olivia, an AI-powered health platform. The platform will collect and combine electronic health records and patient-reported outcomes from over 1,000 healthcare systems. The goal is to create a compreh…
Sponsor: Tempus AI • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Could a lifesaving leukemia drug harm Men's sexual health?
Knowledge-focused Recruiting nowThis study looks at whether tyrosine kinase inhibitors (TKIs), the standard treatment for chronic myeloid leukemia (CML), might be linked to erectile dysfunction (ED) in men. Researchers will track 350 male patients who started TKI therapy, using questionnaires and medical record…
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Blood test may personalize leukemia drug dosing
Knowledge-focused Recruiting nowThis study looks at whether measuring the amount of venetoclax in the blood can help doctors give the right dose to people with newly diagnosed acute myeloid leukemia (AML). Currently, everyone gets the same dose, but drug levels vary a lot between patients. The goal is to find a…
Sponsor: The First Affiliated Hospital of Soochow University • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Can genetics and environment explain lupus in the gullah population?
Knowledge-focused Recruiting nowThis study investigates why African Americans, particularly the Gullah community from the Sea Islands of South Carolina and Georgia, are at higher risk for systemic lupus erythematosus (SLE). By analyzing genetic and environmental factors in 750 participants—including people with…
Sponsor: Medical University of South Carolina • Aim: Knowledge-focused
Last updated Jul 30, 2026 00:00 UTC
-
Can a simple social check improve leukemia care?
Knowledge-focused Recruiting nowThis study looks at whether screening adults with leukemia for social needs (like housing or food) and offering early social work help is practical and helpful. About 80 newly diagnosed patients will either get the screening and consultation or usual care. The goal is to see if t…
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jul 29, 2026 00:00 UTC
-
Tracking the emotional toll of a cancer diagnosis: when does anxiety peak?
Knowledge-focused Recruiting nowThis study follows adults with a suspected bone or soft tissue tumor to see how their stress and anxiety levels change at three critical moments: before biopsy, after learning the diagnosis, and when treatment begins. Participants fill out standard questionnaires about anxiety, d…
Sponsor: Istanbul University • Aim: Knowledge-focused
Last updated Jul 29, 2026 00:00 UTC
-
Which finger or earlobe? a study tests the best spot for oxygen monitoring in lung disease
Knowledge-focused Recruiting nowThis study compares oxygen readings taken from the finger and the earlobe during a six-minute walk test in people with interstitial lung disease. The goal is to see if one location gives more accurate measurements of oxygen levels during exercise. The results could help doctors d…
Sponsor: Hospital de Granollers • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
Could the gut hold the key to calming autoinflammatory Flare-Ups?
Knowledge-focused Recruiting nowThis study investigates whether gut bacteria and the chemicals they produce influence inflammation in people with autoinflammatory diseases such as FMF, CAPS, and MKD. Researchers will analyze stool and blood samples from 300 patients to measure gut-derived metabolites and assess…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
A single blood test may reveal whether a gene tied to transplant outcomes influences psoriatic arthritis risk.
Knowledge-focused Recruiting nowThis study compares the prevalence of the HLA B leader gene in 658 people with psoriatic arthritis and a healthy control group. Researchers will also look at the related HLA B27 gene. The goal is to see whether this genetic marker, already known to affect outcomes in bone marrow …
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
Could early lipid screening in High-Risk kids prevent future heart attacks?
Knowledge-focused Recruiting nowThis study screens children and adolescents aged 5 to 18 who have chronic conditions like congenital heart disease, inflammatory bowel disease, celiac disease, or rheumatic diseases for lipid metabolism disorders. Participants provide a blood sample and complete a questionnaire a…
Sponsor: Alexandra Miriam Kiess • Aim: Knowledge-focused
Last updated Jul 23, 2026 00:00 UTC
-
Massive CML registry launches to reveal how TKIs really perform
Knowledge-focused Recruiting nowThis registry will follow 1,000 adults with chronic-phase CML who are taking approved TKIs (like Gleevec or Tasigna) as their first or second treatment. Over 5 years, researchers will track side effects, treatment changes, and patient-reported experiences to understand how these …
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC
-
New registry aims to unlock mysteries of Pregnancy-Related aortic tears
Knowledge-focused Recruiting nowThis study is a national registry in China that will track 500 women who experience an aortic dissection (a tear in the main artery) during pregnancy or within 12 weeks after giving birth. Researchers will collect information on treatments and outcomes for both mothers and babies…
Sponsor: DeltaHealth Hospital · Shanghai • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
Could stress before shoulder surgery predict complications?
Knowledge-focused Recruiting nowThis study looks at whether patients who feel more stressed before shoulder surgery for rotator cuff problems have a harder recovery. Researchers will measure stress levels in 100 adults using a questionnaire before their operation. The goal is to see if high stress is linked to …
Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Can a simple blood test predict leukemia risk after cancer therapy?
Knowledge-focused Recruiting nowThis study investigates clonal hematopoiesis (CH) — small mutations in blood cells that can arise naturally or after cancer treatment — in adults receiving chemotherapy or radiation for solid tumors like breast, lung, or colorectal cancer. Researchers will collect blood, saliva, …
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
COVID-19's skin secrets: could chilblains hold clues to the virus?
Knowledge-focused Recruiting nowThis study looks at skin problems that appear during a COVID-19 infection, with a special focus on chilblains (painful red or purple bumps on fingers or toes). Researchers want to understand why these skin changes happen—whether from the virus itself, tiny blood clots, or inflamm…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
New biomarker study aims to spot lupus kidney disease earlier
Knowledge-focused Recruiting nowThis study follows 500 adults with lupus to see if blood and urine tests can reliably detect kidney inflammation (lupus nephritis). Participants give samples during routine visits, and doctors track their kidney health over time. The goal is to find simple, non-invasive markers t…
Sponsor: Oslo University Hospital • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
New study aims to unlock secrets of systemic sclerosis through patient samples
Knowledge-focused Recruiting nowThis study is gathering blood, stool, and skin samples from 100 adults with systemic sclerosis to learn more about the disease. Researchers will also track health information like skin thickness, lung function, and quality of life over time. The goal is to build a biobank for fut…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Study links gum health to rare kidney diseases
Knowledge-focused Recruiting nowThis study looks at gum disease in people with rare kidney disorders like Alport syndrome, Fabry disease, and tuberous sclerosis, as well as lupus. Researchers will compare 100 participants to those with chronic kidney disease and healthy controls. They aim to understand how comm…
Sponsor: Stefan Lujinschi • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
New study hopes to find a simple test for MS diagnosis
Knowledge-focused Recruiting nowThis study is analyzing inflammatory markers in the blood and spinal fluid of 300 people who are being checked for multiple sclerosis (MS). The goal is to see if certain markers can help doctors tell MS apart from other autoimmune diseases that affect the brain and spinal cord. R…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Blood bank aims to predict leukemia risk in MDS patients
Knowledge-focused Recruiting nowThis study gathers blood and bone marrow samples from 150 adults with myelodysplastic syndrome (MDS), a blood disorder that can turn into acute leukemia. Researchers want to find biological markers that help predict which patients are likely to progress to leukemia. The goal is t…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Could a Finger-Prick test replace clinic blood draws for arthritis patients?
Knowledge-focused Recruiting nowThis study is testing a new device called BloodTrackR that lets people with rheumatoid arthritis collect a small blood sample at home using a finger prick and a smartphone app. Twenty participants will try the device and answer questions about how easy it is to use. The goal is t…
Sponsor: University of Ulster • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Lupus patients enrolled in major Long-Term observation study
Knowledge-focused Recruiting nowThis study follows 300 adults with systemic lupus erythematosus (SLE) who are seen by a team of specialists at a hospital in Brest, France. Researchers will collect data on disease patterns, symptoms, and test results over time. The goal is to better understand lupus and improve …
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Major study aims to uncover hidden heart disease and test steroid treatment
Knowledge-focused Recruiting nowThis study is tracking 1,500 people with cardiac sarcoidosis—a condition where inflammation affects the heart—to learn how doctors currently diagnose and treat it. Researchers will also test whether corticosteroid therapy improves outcomes. The goal is to create better guidelines…
Sponsor: Ottawa Heart Institute Research Corporation • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New study investigates why some AML patients face early bleeding or clotting risks
Knowledge-focused Recruiting nowThis observational study examines a specific group of patients with a type of acute myeloid leukemia (AML) that has an NPM1 mutation. Researchers want to see if a particular subset, called APL-like, is linked to early blood vessel problems like bleeding or clots. The study will l…
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Rare sinus cancer study aims to clarify treatment outcomes
Knowledge-focused Recruiting nowThis study follows people with a rare and advanced cancer of the nasal cavity and sinuses called T4 sinonasal adenoid cystic carcinoma. All participants receive the standard treatment: surgery followed by radiation therapy. The goal is to measure how long people live without the …
Sponsor: Eye & ENT Hospital of Fudan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Leftover surgery tissue could unlock secrets of hardening arteries and bones
Knowledge-focused Recruiting nowThis study uses leftover tissue from heart and orthopedic surgeries to learn more about how calcification (hardening) happens in bones and blood vessels. Researchers will grow cells from these tissues in the lab to study the process. The goal is to better understand the disease, …
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a skin biopsy tell your doctor which treatment will work?
Knowledge-focused Recruiting nowThis study is collecting skin and blood samples from 830 people with chronic inflammatory skin diseases like psoriasis, eczema, and lupus. Researchers want to find biological markers that can predict how well a person will respond to treatment after one year. The goal is to move …
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
Could your genes cause pelvic pain? new study seeks answers
Knowledge-focused Recruiting nowThis study aims to find out if chronic pelvic pain conditions like prostatitis and interstitial cystitis can be inherited. Researchers will collect DNA and urine from 500 participants, including family members, to look for genetic links. The goal is to better understand the cause…
Sponsor: Boston Children's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
10,000 joint replacements under the microscope: what makes an implant last?
Knowledge-focused Recruiting nowThis study collects information from 10,000 adults who have had hip or knee replacement surgery at Heidelberg University Hospital. Researchers will follow participants during routine check-ups to see how long the artificial joints last, how well they function, and what problems m…
Sponsor: University Hospital Heidelberg • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Scientists hunt for clues to improve leukemia treatment after transplant
Knowledge-focused Recruiting nowThis study looks at blood cells from 20 adults with acute myeloid leukemia (AML) whose cancer returned after a stem cell transplant. All participants have specific genetic changes (NPM1 mutations or KMT2A rearrangements) and are being treated with a menin inhibitor. Researchers w…
Sponsor: University of Freiburg • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Leukemia drug study probes thinking and memory side effects
Knowledge-focused Recruiting nowThis study looks at whether targeted cancer drugs called TKIs affect brain health and well-being in people with chronic leukemia. Researchers will compare 400 patients who receive TKI therapy to those who do not. The goal is to understand if these treatments cause cognitive chang…
Sponsor: University of Rochester NCORP Research Base • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Scientists decode immune clues to improve leukemia treatment
Knowledge-focused Recruiting nowThis study collects blood and bone marrow samples from 80 adults newly diagnosed with acute myeloid leukemia (AML). Researchers will measure inflammasome activity before and after standard chemotherapy to see if it relates to how well the treatment works. The goal is to better un…
Sponsor: Ciceri Fabio • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
No travel needed: new study uses video calls to uncover genetic secrets of childhood muscle disease
Knowledge-focused Recruiting nowThis study aims to learn why myotonic dystrophy type 1 affects children differently than adults, and why symptoms vary even within the same family. Researchers will observe 100 children (ages 0-17) through video calls and simple at-home activities, and analyze their genes from a …
Sponsor: University of Rochester • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
5,000 patients to help unlock secrets of inflammatory heart disease
Knowledge-focused Recruiting nowThis study aims to learn how well heart scans (MRI, ultrasound, PET) can detect and predict outcomes in people with suspected or known inflammatory heart diseases. Researchers will follow 5,000 adults for one year to see how often heart involvement is confirmed and how it affects…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
New study aims to unlock secrets of rare inflammatory diseases
Knowledge-focused Recruiting nowThis study is looking at 50 children and adults with rare autoinflammatory diseases—conditions where the immune system causes inflammation without a clear reason. Researchers want to find what leads to a faster diagnosis, what factors are linked to these diseases, and which treat…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New DNA scanner could spot hidden cancer clues
Knowledge-focused Recruiting nowThis study is testing a new technique called optical genome mapping (OGM) to find genetic changes in blood cancers like polycythemia vera, essential thrombocythemia, and myelofibrosis. Researchers will compare OGM with standard genetic tests in 300 patients who need a bone marrow…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
Hip bone reconstruction after cancer: a 30-Year review
Knowledge-focused Recruiting nowThis study looks back at 150 patients who had surgery to replace the upper thigh bone after removing a bone tumor. Researchers will check medical records and scans to see how long the reconstruction lasts and how well patients can move afterward. The goal is to learn what affects…
Sponsor: Costantino Errani • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
Can we predict chronic pain in teens? new study seeks answers
Knowledge-focused Recruiting nowThis study looks at 600 teens and young adults (ages 14-26) with conditions like juvenile arthritis, fibromyalgia, or past surgeries to understand why some develop long-lasting pain while others don't. Researchers will examine pain sensitivity, immune markers, and social factors …
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Scientists map immune cells in pituitary tumors to unlock new treatments
Knowledge-focused Recruiting nowThis study looks at the immune cells inside pituitary tumors to better understand how they behave. Researchers will analyze tumor samples from 60 adults who are having surgery to remove their pituitary tumor. The goal is to find clues that could lead to new immune-based treatment…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
New imaging method may spot tumor growth earlier after freezing treatment
Knowledge-focused Recruiting nowThis study looks at whether a detailed MRI analysis called radiomics can predict if a desmoid tumor will grow back after cryoablation (freezing treatment) better than standard methods. Researchers will follow 21 patients treated at one hospital to compare radiomics with usual siz…
Sponsor: Istituto Ortopedico Rizzoli • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
New registry aims to unlock secrets of rare skin disease morphea
Knowledge-focused Recruiting nowThis study is creating a registry of 500 children and adults with morphea (localized scleroderma) to track how the disease behaves over time, what complications arise (like arthritis), and whether it has an autoimmune cause. Participants provide medical history and skin assessmen…
Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Could your gums affect your pregnancy? new study investigates
Knowledge-focused Recruiting nowThis study is looking at the gum health and mouth bacteria of 30 women who have had three or more miscarriages. Researchers want to see if there is a connection between certain bacteria in the mouth and pregnancy loss. Participants will have a standard dental checkup and provide …
Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Can we predict RA flares? new study watches remission patients for clues
Knowledge-focused Recruiting nowThis study follows 200 adults with rheumatoid arthritis who are already in stable remission from standard medications. Researchers will track their health over up to 5 years using exams, ultrasound, and X-rays to see who stays well and who has a flare. The goal is to learn how to…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Scientists launch effort to crack the code of rare childhood blood cancers
Knowledge-focused Recruiting nowThis study is collecting information from 260 children and teens with rare blood cancers called myelodysplastic syndromes (MDS) and juvenile myelomonocytic leukemia (JMML). Researchers are using advanced genetic tests to improve how these diseases are diagnosed and classified. Th…
Sponsor: University Hospital Freiburg • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Can a 14-Day trial boost app use for back pain patients?
Knowledge-focused Recruiting nowThis study looks at how to make it easier for people with axial spondyloarthritis to start using the Axia app. Two groups of 200 participants will get different onboarding brochures: one with standard instructions and one with a 14-day free trial. Researchers will track how many …
Sponsor: Wuerzburg University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Can a simple blood test predict arthritis drug success?
Knowledge-focused Recruiting nowThis study is testing whether a mathematical model using blood markers can predict how well rheumatoid arthritis patients will respond to a lower dose of the drug rituximab. Thirty adults with RA who already do well on standard-dose rituximab will switch to a lower dose. Research…
Sponsor: University Hospital, Tours • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC